Attached files

file filename
EX-32 - EX 32.2 SEC 906 CERTIFICATION-CFO - PARALLAX HEALTH SCIENCES, INC.ex322sect906certcfo123117.htm
EX-32 - EX 32.1 SEC 906 CERTIFICATION-CEO - PARALLAX HEALTH SCIENCES, INC.ex321sect906certceo123117.htm
EX-31 - EX 31.2 SEC 302 CERTIFICATION-CFO - PARALLAX HEALTH SCIENCES, INC.ex312sect302certcfo123117.htm
EX-31 - EX 31.1 SEC 302 CERTIFICATION-CEO - PARALLAX HEALTH SCIENCES, INC.ex311sect302certceo123117.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-K

 

(Mark One)

 

 ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934

 

For the fiscal year ended December 31, 2017

 

 TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES 
 EXCHANGE ACT OF 1934

 

Commission file number 000-52534

 

PHS-logo-032918.jpg 

 

PARALLAX HEALTH SCIENCES, INC.

 

(Exact name of registrant as specified in its charter)

 

Nevada

46-4733512

(State or other jurisdiction of incorporation or organization)

(I.R.S. Employer Identification No.)

 

 

1327 Ocean Avenue, Suite B, Santa Monica, CA

90401

(Address of principal executive offices)

(Zip Code)

 

 

Registrant's telephone number, including area code:

(310) 899-4442

 

Copy of all Communications to:

Peter Hogan, Esq.

Buchalter

1000 Wilshire Blvd., Suite 1500

Los Angeles, CA 90017

(213) 891-0700

 

 

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 the Securities Act.

Yes ☐ No ☑

 

 

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.

Yes ☐ No ☑

 

 

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports) and (2) has been subject to such filing requirements for the last 90 days.

Yes ☐ No ☑

 

 

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Website, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registration statement was required to submit and post such files).

Yes ☐ No ☑

 

 

Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K (§229.405 of this chapter) is not contained herein, and will not be contained, to the best of registrant's knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K.

Yes ☐ No ☑

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See definition of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer

 

Accelerated filer

Non-accelerated filer

 

Smaller reporting company

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Yes ☐ No ☑

 

The aggregate market value of Common Stock held by non-affiliates of the Registrant as of June 30, 2018 was $8,253,020, based on a closing price of $0.1524 for the Common Stock on June 30, 2018, the last business day of the Registrant’s most recently completed second fiscal quarter. For purposes of this computation, all executive officers and directors have been deemed to be affiliates. Such determination should not be deemed to be an admission that such executive officers and directors are, in fact, affiliates of the Registrant.

 

Indicate the number of shares outstanding of each of the registrant’s

classes of common stock as of the latest practicable date.

 

146,425,660 common shares issued and outstanding as of September 7, 2018




TABLE OF CONTENTS

 

 

 

ITEM 1.

BUSINESS

1

 

 

 

ITEM 1A.

RISK FACTORS

20

 

 

 

ITEM 2.

PROPERTIES

20

 

 

 

ITEM 3.

LEGAL PROCEEDINGS

20

 

 

 

ITEM 4.

MINE SAFETY STANDARDS

22

 

 

 

ITEM 5.

MARKET FOR COMMON EQUITY AND RELATED STOCKHOLDER MATTERS

23

 

 

 

ITEM 6.

SELECTED FINANCIAL DATA

24

 

 

 

ITEM 7.

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

25

 

 

 

ITEM 7A.

QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISKS

33

 

 

 

ITEM 8.

FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA

33

 

 

 

ITEM 9.

CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE

34

 

 

 

ITEM 9A.

CONTROLS AND PROCEDURES

34

 

 

 

ITEM 9B.

OTHER INFORMATION

35

 

 

 

ITEM 10.

DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE

35

 

 

 

ITEM 11.

EXECUTIVE COMPENSATION

39

 

 

 

ITEM 12.

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS

41

 

 

 

ITEM 13.

CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE

42

 

 

 

ITEM 14.

PRINCIPAL ACCOUNTANTS FEES AND SERVICES

43

 

 

 

ITEM 15.

EXHIBITS, FINANCIAL STATEMENT SCHEDULES

44

 

 

 

 

 

PART I

 

ITEM 1.BUSINESS 

 

This annual report contains forward-looking statements. These statements relate to future events or future financial performance of Parallax Health Sciences, Inc. (“Parallax” or the “Company”), and include statements made by the Company regarding pharmaceutical insurance reimbursements, State Licenses, product development and obtaining FDA clearances. In some cases, forward-looking statements can be identified by terminology such as “may”, “should”, “expects”, “plans”, “anticipates”, “believes”, “estimates”, “predicts”, “potential” or “continue” or the negative of these terms or other comparable terminology. These statements are only predictions and involve known and unknown risks, uncertainties and other factors” that may cause the Company’s or its industry’s actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements.

 

Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, it cannot guarantee future results, levels of activity, performance or achievements. Except as required by applicable law, including the securities laws of the United States, the Company does not intend to update any of the forward-looking statements to conform these statements to actual results.

 

The Company’s financial statements are stated in United States Dollars (US$) and are prepared in accordance with United States Generally Accepted Accounting Principles.

 

In this annual report, unless otherwise specified, all dollar amounts are expressed in United States Dollars and all references to “common shares” refer to the common shares in the Company’s capital stock.

 

As used in this annual report, the terms “the Company”, "we", "us", "our", and "Parallax" mean Parallax Health Sciences, Inc., and its wholly-owned subsidiaries, Parallax Diagnostics, Inc., Parallax Health Management, Inc. (formerly Qolpom, Inc.), RoxSan Pharmacy, Inc. and Parallax Behavioral Health, Inc., unless otherwise indicated.

 

CORPORATE OVERVIEW

 

The Company’s principal executive office is located at 1327 Ocean Avenue, Suite B, Santa Monica, California, 90401. The Company’s telephone number is (310) 899-4442.

 

The Company’s websites are at www.parallaxhealthsciences.com, www.parallaxdiagnostics.com, www.roxsan.com and www.parallaxhealthmanagement.com.

 

The Company is a reporting Company with its stock traded on the OTC Markets under the symbol “PRLX”. (OTCQB.PRLX).

 

Parallax Health Sciences, Inc. is an innovative biomedical health-care company headquartered in Santa Monica, California, with four divisions: Pharmaceuticals, Diagnostics, Remote Patient Monitoring and Behavioral Health. Each of these divisions target a separate vertical market that are synergistic, compliment, and strengthen each other and the Parallax value proposition as a whole.

 

CORPORATE HISTORY

 

Formation and Development

 

The Company was incorporated in the State of Nevada on July 6, 2005.  On November 1, 2012, the Company, formerly Endeavor Power Corporation, and its wholly-owned subsidiary Endeavor Holdings, Inc., a Nevada corporation, entered into an Agreement and Plan of Merger with Parallax Diagnostics, Inc., a Nevada corporation, whereby Parallax Diagnostics became a wholly-owned subsidiary. On January 9, 2014, the Company changed its name to Parallax Health Sciences, Inc.

 

The Company’s mission is simple; improving the quality of healthcare, while reducing costs.  The Parallax business was founded on its point of care diagnostic business, Parallax Diagnostics, Inc., in 2010, when Parallax acquired the right, title, and interest, through an exclusive License with Montecito BioSciences, Ltd. (“MBS”), to develop, manufacture and commercialize the Target System, an Immunoassay point-of-care diagnostic testing system. Concurrently, through an Assignment Agreement with MBS, Parallax acquired the right, title, and interest to twenty-six (26) FDA-cleared tests in the area of infectious disease, medical conditions, drugs of abuse, cardiac and pregnancy, that are designed to be utilized with the Target System.  In 2015, the Company acquired Parallax Health Management, Inc. to expand into the Telehealth and Remote Patient Monitoring market, and in 2017, Parallax Behavioral Health, Inc. was formed to incorporate the patented Platform for Optimizing Data Drive Outcomes, (the “Intrinsic Code”) technology (formerly REBOOT) into Parallax’s products and services.

 

The Company continually strives to identify solutions to the challenges facing the current healthcare system in the United States and markets around the world.  The Company is committed to delivering quality products and services to patients, payers, healthcare insurers and stakeholders that are accessible and reasonable, and are built upon sound business models designed to provide for sustainable growth and continued increased value to the Parallax shareholders.

 

Parallax’s current family of companies that serve as the foundation for its cross-over business model of operations include:

 

Parallax Diagnostics, Inc. ("Parallax Diagnostics" or "PDI") is the Company’s point of care diagnostic testing company focused on the exploitation of a proprietary diagnostic immunoassay testing platform and test cartridges for the areas of infectious diseases, cardiac markers, drugs of abuse and various other medical conditions. Parallax’s primary focus is to commercialize the Target System worldwide. PDI is currently pre-revenue.

 

RoxSan Pharmacy, Inc. (“RoxSan”), acquired in the 3rd quarter of 2015, is the Company’s 62-year-old, Beverly Hills, California based compound pharmacy that is licensed to operate in over 40 States.

 

Parallax Health Management, Inc. (formerly Qolpom, Inc.) (“PHM”) a Tucson, Arizona based Remote Patient Monitoring (“RPM”) business is the Company’s most recent acquisition, and represents an opportunity to develop products and services, and commercialize them, on a proprietary platform, in the RPM and Telehealth market, that will allow for systems integration with a number of third party services and solutions. In 2016, PHM initiated the generation of revenue through the deployment of its services and products.

 

Parallax Behavioral Health, Inc. (“PBH”), a Delaware corporation, was formed by the Company in 2017, and acquired the intellectual property known as REBOOT, the acronym for Reliable Evidence-Based Outcomes Optimization Technologies.  In 2018, the Company rebranded the technology as Intrinsic Code (the “Intrinsic Code”), a software platform specifically designed to improve health treatment outcomes through Internet-based and mobile behavioral technology systems that enable its users and user groups to more effectively achieve goals within a prescribed timeline




Acquisition of Parallax Health Management, Inc. (formerly Qolpom, Inc.)

 

As part of the Company’s strategic plan to obtain a platform to enhance its diagnostic tests, on August 31, 2016 (the “Execution Date”), the Company entered into an agreement with Qolpom, Inc., an Arizona corporation in the remote healthcare monitoring and telehealth business (“Qolpom”) and its shareholders (the “Seller”) to purchase 100% of the issued and outstanding shares of Qolpom’s common stock and its assets, inventory and intellectual property.  The Purchase Agreement was fully executed on September 20, 2016, and the transaction was completed (the “Closing Date”). The Qolpom name was later changed to Parallax Health Management, Inc. (“PHM”).

 

Pursuant to the Qolpom Agreement, in exchange for 100% of the Qolpom stock and 100% of Qolpom’s assets, inventory and intellectual property, among other things, consideration to the Seller included:

 

5,000,000 shares of the Company’s common stock; and 

2,500,000 options to purchase shares of the Company's common stock, to be granted one year from the Execution Date, and vesting over three (3) years, of which 500,000 are exercisable at $0.10, 1,000,000 are exercisable at $0.15, and 1,000,000 are exercisable at $0.25; and 

10% of revenues generated from PHM business segment, up to $1,000,000; and 7% thereafter, up to $2,000,000; and 

3% of revenues generated from the sale of Qolpom hardware and monitoring service fees. 

 

Formation of Parallax Behavioral Health, Inc.

 

On March 22, 2017, the Company formed a wholly-owned subsidiary, Parallax Behavioral Health, Inc. (“PBH”), a Delaware corporation.

 

On April 26, 2017, pursuant to a resolution of the board of directors, the Company, through its wholly-owned subsidiary, Parallax Behavioral Health, Inc., completed the acquisition of 100% of certain intellectual property from ProEventa Inc., a Virginia Corporation (“ProEventa”), in accordance with the Intellectual Property Purchase Agreement between the Company, PBH and ProEventa (the “ProEventa Agreement”). ProEventa has an expertise in the development of behavioral health technologies, and is the wholly-owned subsidiary of Grafton Integrated Health Network, Inc., a non-profit Virginia corporation (“Grafton”), Pursuant to the ProEventa Agreement, in exchange for 100% of that certain intellectual property, among other things, consideration to ProEventa included:

 

a stock purchase agreement to purchase 2,500,000 shares of the Company’s common stock; and 

a revenue sharing agreement, providing for a cash earn-out to be paid to the ProEventa shareholders of up to $3,000,000, to be derived from certain net revenue generated by the Company, as defined in the agreement; and 

a royalty agreement, providing for a royalty of 3% of the revenues generated from the intellectual property, ending at such time as Parallax has paid ProEventa $25,000,000; and 

a limited license to ProEventa for the use of certain of the Intellectual Property's technology at Grafton Schools. 

 

On April 26, 2017, in conjunction with the ProEventa Agreement, the Company entered into a consulting agreement with James Gaynor that, among other things, provides for consideration to Mr. Gaynor as follows:

 

a stock purchase agreement to purchase 500,000 shares of the Company’s common stock at $0.001 per share; and 

a grant of options to purchase 1,000,000 shares of the Company's common stock at a price of $0.25 per share, vesting annually over a three (3) year period beginning September 1, 2017. 

 

Acquisition of RoxSan Pharmacy, Inc.

 

In August 2015, Parallax acquired RoxSan Pharmacy, Inc. ("RoxSan"), a California corporation after negotiating the economic terms of the acquisition based on certain representations and warranties of the seller.  The Company's initial interest centered on utilizing the acquisition as a means of accelerating the commercialization of the Parallax Target System and diagnostic platform, as RoxSan had access to a nationwide network of doctors and sales representatives.  During the due diligence process, the Company became aware of the numerous opportunities that RoxSan and its markets represented.

 

On March 21, 2013, the Company entered into a Letter of Intent with Shahla Melamed, RoxSan's sole Shareholder, to acquire RoxSan and between March 2013 and August 2015, four (4) amendments were also executed that led to the final Sale and Purchase Agreement.

 

As part of the acquisition, the Company was required to obtain licensure from the State of California, and on July 31, 2015, the Company received notice that its pharmacy and sterile compounding licenses were issued by the California State Board of Pharmacy.

 

On August 13, 2015 (the "Closing Date"), pursuant to a resolution of the board of directors (the "Board"), the Company entered into an Agreement to Purchase and Sell One Hundred Percent of the Issued and Outstanding Shares of RoxSan Pharmacy, Inc. ("RoxSan" or the "Pharmacy"), and its Assets and Inventory (the “Purchase Agreement”).  Pursuant to the Purchase Agreement between the Company, RoxSan and its sole shareholder, Shahla Melamed (the “Seller” or "Melamed"), in exchange for 100% of RoxSan's common stock, and its assets and inventory, the Company, among other things, issued the Seller a Secured Promissory Note (the "Note") dated August 13, 2015 in the amount of $20.5 million (the "Acquisition").  The Note bears interest at a rate of 6% per annum, and matures in three (3) years, or August 13, 2018 ("Maturity").  The Company is seeking a reduction in the Purchase Price and related promissory note (See Legal Proceedings).  As a result of the Acquisition, effective August 13, 2015, RoxSan became a wholly-owned subsidiary of the Company. No change in control of the Company occurred as a result of the Acquisition.

 

Closure of RoxSan Pharmacy, Inc.

 

Since the Company’s acquisition of RoxSan, the deleterious actions against the pharmacy by the former owner, including, among other things, interference with management and operations, and attempts to damage and/or divert customer and vendor relationships, had a significant adverse impact on the pharmacy. Furthermore, the discovery of the former owner’s alleged involvement in suspected insurance fraud caused RoxSan’s contract with its primary IVF drug rebate program to be terminated in August 2016. As a result, RoxSan was no longer eligible to receive incentive rebates for the majority of its IVF drug purchases, which were key to the profitability of the IVF drug sales; and for which without the rebates, RoxSan was unable to provide its customers with comparably priced IVF drugs.  This, among other things, caused a precipitous drop in RoxSan’s IVF revenues, and ultimate exit from the IVF market in mid-2017.  Soon thereafter, in July 2017, RoxSan’s contract with its primary drug supplier was terminated for similar reasons connected to the former owner and alleged criminal activities associated with the Melamed family name, despite the Company’s new ownership and management. After careful consideration, the Company determined that RoxSan was unable to generate enough profits to sustain its pharmacy business, and in December 2017, the pharmacy ceased operations.

 

On May 14, 2018, pursuant to a unanimous resolution of the Boards of Directors of RoxSan Pharmacy, Inc. and Parallax Health Sciences, Inc., RoxSan filed a Chapter 7 petition in the United States Bankruptcy Court for the Central District of California.  Mr. Timothy Yoo was appointed trustee on May 15, 2018.  In connection with this filing, RoxSan seeks to discharge approximately $5 million of liabilities owed to various parties including more than $1 million owed to the Company.


Table of Contents

- 3 -



Changes in Management

 

On December 29, 2016, Mr. John L. Ogden and Ms. Calli R. Bucci were elected to serve as members of the Company's board of directors.  

 

On April 6, 2017, the Board elected Mr. J. Michael Redmond as Chairman, to serve until the Company’s next meeting, in accordance with the Company's bylaws, or a resignation is duly tendered.

 

Effective July 7, 2017, the Board of the Company has caused the departure of Mr. Redmond from his position as President and Chief Executive Officer of the Company and its wholly-owned subsidiary, RoxSan Pharmacy, Inc. Pursuant to the Employment Agreement dated August 1, 2015, a resignation from the Board of the Company and its wholly-owned subsidiaries, RoxSan Pharmacy, Inc. and Parallax Health Management, Inc. was tendered automatically.

 

Effective July 7, 2017, pursuant to a unanimous Board resolution, Mr. Paul R. Arena was appointed as the Company’s President and Chief Executive Officer, and the Board caused Mr. Arena's election to the Company's Board and the Board of its wholly-owned subsidiaries, RoxSan Pharmacy, Inc. and Parallax Health Management, Inc.

 

On July 7, 2017, in connection with Mr. Arena’s appointment, the Company entered into an Executive Employment Agreement (the “Agreement”) with Mr. Arena dated July 7, 2017, wherein Mr. Arena will serve as President and Chief Executive Officer for a period of three (3) years.  As compensation for his services, Mr. Arena will receive a base compensation of $350,000 in year one, of which 30% shall be deferred until certain funding goals are met, $425,000 in year two, and $550,000 in year three, as well as annual bonus compensation equal to 2x base when certain Company earnings are reached.  In addition, the Agreement includes a grant to purchase 10,000,000 restricted common shares at $0.001 per share, of which 25% vests immediately; 25% vests in one year; 25% vests after two years; and 25% vests when certain funding goals have been met.  The shares were valued at $2,000,000, of which $500,000 was expensed, and $1,500,000 was deferred, to be amortized over the next thirty-six (36) months. The Agreement also includes the grant of 5,000,000 stock options at an exercise price of $0.25 per share.  The options are exercisable for a period of five years, and vest when certain market share prices of the Company’s common stock are met.

 

On July 26, 2017, Mr. Jorn Gorlach resigned as a member of the board of directors.  This resignation did not involve any disagreements with the Company.

 

On June 4, 2018, Mr. Anand Kumar resigned as a member of the board of directors.  This resignation did not involve any disagreement with the Company.  Mr. Nathaniel T. Bradley, currently serving as Chief Technology Officer, succeeds him; to serve as a member of the board of directors until the next annual meeting of the shareholders and/or until his successor is duly appointed.

 

 

DESCRIPTION OF BUSINESS

 

Overview

 

The Company’s principal focus is on personalized patient care through pharmacy services provided by RoxSan, remote healthcare services provided by Parallax Health Management, Inc. (formerly Qolpom, Inc.), behavioral health systems provided by Parallax Behavioral Health, Inc., and eventually through the Parallax Diagnostics Inc.'s medical diagnostic testing platform, which holds the exclusive license, with rights and title to the Target System, an Immunoassay point-of-care diagnostic testing system and certain Target System point of care immunoassay diagnostic tests.

 

Parallax’s divisions are:

 

Medical Diagnostics

Parallax Diagnostics, Inc.

Point-of-care diagnostics

Pre-revenue

Pharmaceuticals

RoxSan Pharmacy, Inc.

62-year-old Beverly Hills, CA pharmacy licensed in over 40 US states (1)

Remote Health Care

Parallax Health Management, Inc.

Patient-to-Medical regimen technology, remote patient monitoring and telehealth

Generated just under $1 million during its initial trial campaign

Behavioral Health Systems

Parallax Behavioral Health, Inc.

Intrinsic Code technology

Pre-revenue

 

Each of Parallax's divisions target a separate vertical market that complement each other and the Company's value proposition. In addition, the synergistic operational cross-over affords Parallax the ability to use built-in economies of scale across multiple operating platforms.  

 

(1)During 2017, Parallax’s operations included RoxSan Pharmacy, Inc.  However, the pharmacy was forced to cease operations in December 2017 (see Corporate History and Legal Proceedings).  

 

The Parallax Business Model

 

In the past 60 years, healthcare has transitioned from a direct relationship between doctor and patient, to one that has patients separated from their doctors by the introduction of a huge number of stakeholders, ranging from health insurers, employers, pharmacy benefit managers, imaging, diagnostic testing, lawyers, specialists and a plethora of others.  The patient and healthcare provider both want the same thing: information, quality of service, transparency, value for their hard-earned dollars, and more time in their day.

 

Parallax has developed, acquired and licensed multiple proprietary and exclusive platforms, that provide services and products, across the healthcare continuum.  These platforms are designed to allow for multiple points of reciprocal consideration, through innovative business models, that provide patients with increased quality of services and products, at reduced cost of time and money.  They also provide healthcare providers with increased access to their patients, the ability to deliver better and more efficient service and increase their income from the services they supply.


- 4 -



Products and Services

 

Parallax believes that its products and services can provide solutions that mitigate rising costs, reduce waste in spending through transparency, reduce the amount of unnecessary services, and increase the health and wellness of patients before they are sick.  

 

The pharmacy’s products and services range from pharmaceutical, infertility and compound drugs and medications to retail and over-the-counter drugs and products. RoxSan also provides door-to-door delivery, as well as overnight shipments.

 

Remote health care products include patent pending software and mobile apps and services, as well as electronic kits and devices from third-party licensed platforms that are designated towards a patient’s primary health concern (i.e. diabetes, blood pressure, cardiovascular, general monitoring, etc.), and offer both audio and video options that interface with the patient’s healthcare providers. Prescription medication dosage monitoring is also available.

 

Behavioral health products include the proprietary behavioral health technology, Intrinsic Code, which powers decision support that can also be delivered securely to any internet connected device.  The software can be used by an individual or an organization of any size, with the potential to transform the cost of treating and managing chronic illnesses such as pulmonary-COPD-asthma, diabetes, and cardiovascular disease by effecting the modification of behavior in patients being treated for these chronic diseases.

 

The Cross-Over and Cross-Pollination Model

 

The Company's business model is built on identifying opportunities represented by one market vertical that provides for a separate vertical to utilize one or more of its core operations. Although Parallax’s multiple operations are focused in separate vertical markets, Parallax has designed its business model to allow for cross-pollination and reciprocal transfer of value at multiple points in their respective economic food chains.

 

As an example of the Company's cross-over and cross-pollination model, each of Parallax’s divisions can support each other:

 

RoxSan Pharmacy sells its drugs to doctors in over 40 US states, approximately 3,500 doctors in its client data base, both active and non-active; and 

Parallax Health Management, Inc. can provide a range of after-care products and services, and can sell its telehealth and remote patient monitoring services directly to the doctors being sold compounded medications; and 

Parallax Diagnostics, Inc. the point-of-care testing and diagnostics division, will be able to sell their testing platforms and tests to the RoxSan doctors for use with their patients. 

Parallax Behavioral Health, Inc. can offer its software and Intrinsic Code technology systems to the Parallax clientele. 

 

The Company's business strategy is to expand through organic growth, selective synergistic acquisition, and develop, license and or acquire, quality products and or services that complement the Parallax mission.

 

The Company believes that the current healthcare system is built on unsustainable models and significant challenges for all the stakeholders in the healthcare system. The Company strives to identify products, services and technologies that deliver solutions that fill a void in the current market for high quality high efficacy products and services delivered at reasonable and rational prices.

 

Management

 

Parallax is led by experienced veterans from the healthcare, technology, finance and management fields.  The Company's disciplined and organized approach is balanced by its optimism for the future, and the opportunities present in the current healthcare market. The Parallax team is grounded in a belief that success in business is built on a combination of research, planning and execution.

 

At Parallax, management continually strives to identify solutions to the challenges facing the current healthcare system.  Parallax and its management team of professionals is committed to delivering the highest quality products and services to patients, payers, healthcare insurers and stakeholders that are accessible and reasonable, and are built upon sound business models and economics that are designed to provide for sustainable growth and increased value to the Company's shareholders.

 

Operating Segments

 

Currently, the Company's business operations generate revenue through multiple economic models, ranging from cash payments, insurance reimbursements and pharmaceutical drug rebates derived from its compounding, retail and fertility business, to PHM’s initial remote patient monitoring activity, the deployment of its Good Health Outcomes Platform, integration of Intrinsic Code technology, and the sale of third-party vendor devices.

 

The Company’s 2017 operations included the following segments:

 

Pharmacy 

 

RoxSan provides a full range of pharmacy services including retail, compounding and fertility medications.  RoxSan generates net revenues primarily by dispensing prescription drugs, both through local channels by direct delivery as well as mail order. RoxSan also sells a wide assortment of general merchandise, including over-the-counter drugs, beauty products and cosmetics, seasonal merchandise and convenience foods, through the Company’s pharmacy.  The pharmacy is fully licensed and qualified to conduct business in over 40 US States.  

 

Remote Patient Monitoring  

 

PHM provides a first-of-its-kind technology platform that provides for the complete remote patient care delivery system: the patent-pending Good Health Outcomes, which utilizes proprietary software and technology to bridge clinical behavioral science with technology and logistics for payers, providers and clinical professionals across a variety of wellness and clinical devices, including both fitness and clinical applications. PHM’s Good Health Outcomes is a secure and scalable platform for collecting, transmitting and analyzing biometric, pharmaceutical, and health data to healthcare providers, primarily hospitals, accredited nursing operations, and physicians.

 

PHM generates revenues through fees charged for the license and utilization of its proprietary system that provides software integrations of the Good Health Outcomes platform.  Additionally, PHM generates incremental revenues through the delivery of acute, post-acute and chronic health patient management software systems that enable PHM customers to bill for and collect payments from patients and third-party payers for telemonitoring and remote services that they deliver.

 

Behavioral Health Systems 

 

In April 2017, the Company, through its wholly-owned subsidiary, Parallax Behavioral Health, Inc., acquired the intellectual property known as REBOOT, the acronym for Reliable Evidence-Based Outcomes Optimization Technologies.  In 2018, the Company rebranded the technology as Intrinsic Code, a software platform specifically designed to improve health treatment outcomes using proprietary behavioral technology systems, that enables its users and user groups to more effectively achieve goals within a prescribed timeline. Through the Company’s proprietary behavioral health technology, Intrinsic Code powers decision support that can also be delivered securely to any internet connected device. The software can be used by an individual or an organization of any size.

 

PBH generates revenues primarily through licensing and subscription of the Intrinsic Code technology platform and systems. As of December 31, 2017, the  BHS segment had not yet begun full operations, generating limited test market sales.

 

Corporate  

 

The Corporate Segment provides management and administrative services to support the Company and consists of certain aspects of the Company’s executive management, corporate relations, legal, compliance, human resources, and corporate information technology and finance departments.  In addition, the Corporate Segment supports the costs and operating expenses related to the continued development and exploitation of the Company's proprietary medical diagnostic and monitoring platform and processes, which remains the Company's primary focus.  


Table of Contents

- 5 -



PARALLAX DIAGNOSTICS, INC.

TARGET SYSTEM and DIAGNOSTIC TESTING PLATFORM

 

Overview

 

Parallax Diagnostics, Inc. (“PDI” or "Parallax Diagnostics") is a company focused on the development of point-of-care diagnostics, with an emphasis on its Target System testing platform and novel applications that detect and/or monitor infectious diseases, cardiac markers and drug of abuse assays.  PDI holds exclusive licenses, in perpetuity, to a line of proprietary, patented and/or patent-pending, previously FDA cleared, point-of-care diagnostic tests to be utilized with its single platform diagnostic testing Target System.  PDI, with its products and products in development, offers the potential to transform the diagnostic landscape by transitioning critical tests from the centralized lab directly to the hands of the physician or clinicians.  

 

Parallax Diagnostics is currently pre-revenue and continues to pursue viable opportunities for the commercialization of its product.  Additionally, Parallax Diagnostics has sought to identify strategies that would make its proposition more valuable and competitive.  The Company has made the strategic decision to keep the Parallax Diagnostics product line off the market, and has spent the last few years prosecuting its patents. Since the inception of Parallax Diagnostics, and the Company has been issued patents on core technology of its technology for its Target System.  In 2014, 2015 and 2017, Parallax Diagnostics and its license partner, Montecito BioSciences, Ltd. ("MBS"), received patents on its mobile testing platform in conjunction with its Target System cartridges in the United States, China, Hong Kong, Macao, and India. To this end, the Company has pursued patents around its foundational technology and the SPARKS Mobile diagnostic reader. PDI also has a technology that was previously cleared by the FDA technology that is being used as a platform for a test that will detect CD4 and CD8 cells which in turn determine a patient’s immune status.

 

Product Strategy

 

In recent years, there has been a continuing shift from the use of laboratory-based analyzers to point-of-care (“POC”) tests that can be performed in a matter of minutes. Unlike the centralized clinical laboratory segment of the diagnostic market, which is mature and highly competitive, the POC market is still in its relatively early stages. According to the recent worldwide research reports, however, such as the 2010 Worldwide IVD Market, by the research firm Kalorama Information, the growth rate of the POC market continues to rise. Although certain simple, single analyte diagnostic tests have been developed, such tests have remained incapable of precise and highly sensitive quantitative measurements. As a result, medical tests that require precise quantization of the target analyte have remained the domain of immunoassay analyzers in the centralized laboratory.

 

Point-of-care diagnostic kits typically consist of test strips that the healthcare provider applies a patient’s sample to and then reads the strip either visually or with an instrument in order to determine a result.  They are simple to use, fast, disposable and reliable within an acceptable range. More sensitive analytes or tests requiring quantitative analysis and definitive antibody screening needed in most situations, must be sent out to a diagnostic lab, and hours or days later results arrive. These tests are comparatively complex, expensive, and time consuming; only centralized diagnostic facilities can manage sample handling and the cost of instruments and reagents.  A point-of-care instrument that has the advantage of a test strip device in terms of ease of use and rapid results along with ELISA-like capabilities for major diseases would circumscribe diagnosis routinely within the course of a patient visit. This could disrupt the current model.  The Company is planning to develop just such a device that it intends to sell to doctors and healthcare providers.

 

The commercial success of the current generation of small, simple to use diagnostic devices which provide rapid results in POC applications has been limited by their inability to provide precise, highly sensitive, quantitative measurement.  Despite these limitations, the rapid increase in discovery of individual markers of disease processes, coupled with the advancements in rapid detection technologies, has made these tools available to medical professionals on a wide scale and POC diagnostics are quickly becoming a high growth industry.

 

The Company’s Target System (the system includes the VT-1000 Desktop Analyzer, the Target Antigen Detection Cartridge and associated reagents) technology addresses these limitations by applying sophisticated immunochemical and optical methods to detect and quantify analytes present in various human specimens, including blood, urine, and feces. Data indicates that sensitivity will be comparable to expensive and complicated laboratory-based analyzers. The Company believes that there is market potential for advanced POC diagnostic products that provide quick and accurate diagnosis during a patient visit, shortening the decision time to medical intervention and minimizing the need for additional patient follow-up, thereby reducing overall healthcare delivery costs.

 

The Company also believes that there is growth opportunity for the exploitation of its Target System platform in developing nations and regions such as Africa, India, South America, Eastern Europe, Russia and Asia as well as developed markets of North America and Western Europe. One of the first initiatives to be developed for this market will combine the Company’s SPARKS Mobile (a portable hand-held diagnostic analyzer based on the VT-1000 Desktop Analyzer technology, but smaller and more portable), currently in development, with a test for the monitoring of AIDS/TB patients through the use of a proprietary rapid point-of-care immunoassay CD4-CD8 test called PROMISE CD4, also in development.

 

The Diagnostics Products

 

The Company’s assets include a previously FDA-cleared VT-1000 Desktop Analyzer and more than two dozen FDA 510(k) cleared diagnostic tests.  The Desktop Analyzer and immunoassay system incorporates a flow-through rapid antigen test platform configuration that has the ability to produce high-performance quantitative blood test results with the ease of rapid qualitative diagnostic strips.  The Company has patents and patent applications related to its current and future products, as well as methods for future test development. The Target VT-1000 Desktop Analyzer is ideally suited for rapid development and commercialization of all new tests that may be introduced.

 

VT-1000 Desktop Analyzer: Quantitative and Qualitative Immunoassay

 

The Company’s VT-1000 Desktop Analyzer was FDA 510(k) cleared and is capable of rapidly detecting qualitative and quantitative data for the Company’s FDA-cleared Target Platform tests.  The VT-1000 Desktop Analyzer is used for all Target Platform Tests, allowing for clinical personnel to be trained once and also gives consistent results for either qualitative or quantitative testing. The Company plans to develop the SPARKS Mobile, a hand-held analyzer unit, similar in size to a mobile phone/PDA, which will be based on the VT-1000 Desktop Analyzer (see Products in Development).

 


- 6 -



Target Antigen Detection System (“TADS”)

 

The Target Antigen Detection System consists of a unique disposable cartridge with reagents capable of testing multiple test markers, combined with the VT-1000 Desktop Analyzer. The TADS requires a small amount of sample and provides results in minutes.  The simplicity of the fully loaded disposable test cartridge and subsequent ease-of-use of the instrument helps to alleviate the technical burden on medical staff and makes patient diagnosis more efficient.

 

The Company’s Target Antigen Detection System is a departure from the standard devices typical to the rapid testing markets. The device is part of the manufacturer’s qualitative and quantitative “Target System Diagnostics Platform,” which offers an array of improved modifications and features to the traditional qualitative and semi-quantitative flow-through immunoassay test. With its platform uniformity, vacuum pump, absorption layer for sample overflow, and complete compatibility with single and multi-light source reflectometer technology, the TADS cartridge is a unique collection of tests for qualitative and quantitative detection diseases and of conditions. The TADS cartridge utilizes a vacuum technology to deposit specimen samples uniformly on test membranes.  The Vacuum Control Flow Device provides a vacuum pump action, which reduces test time and ensures maximum contact with the membrane antibodies.  This collection device allows for numerous tests to be incorporated. The vacuum specimen filtration and excess specimen absorption is built right in.

 

Additional Products Planned for Development

 

The Target System provides the platform for the development of a series of quantitative tests for important diagnostic applications that can provide results at a patient's bedside, in a doctor's office, in the emergency room, in a clinic, in an ambulance, on the battlefield, on site agri-business locations, rural and economically disadvantaged areas.  The Target System expects to meet the POC diagnostic market criteria as follows:

 

Rapid turnaround time 

Direct application of a non-critical volume or placement of sample directly into instrument 

Disposable device or minimal maintenance required 

Minimal technical expertise required 

Positive identification and specimen tracking strategy that eliminates specimen identification errors 

Simple strategy for calibration and QC 

Transferability of data to the LIS or HIS 

Agreement of result with accepted "Gold Standard" tests 

Affordable cost 

 

The Company also believes that there is growth opportunity for the exploitation of the Target System platform in developing nations and regions such as Africa, India, South America, Eastern Europe, Russia and Asia as well as developed markets of North America and Western Europe.  One of the first initiatives for the development of this specific market will be to combine the SPARKS Mobile, the Company’s hand-held analyzer (the portable version of its VT-1000 Desktop Analyzer), with a test for the monitoring of HIV/AIDS patients and Tuberculosis patients, through the use of the Company’s proprietary rapid POC immunoassay PROMISE CD4 quantitative test, also planned for development.

 

The Company’s testing system is not limited to HIV or AIDS diagnostics. The test format has been applied in the past to viral and bacterial infections (e.g., Rubella, Rotavirus, Strep. A) and can be adapted towards other epidemics. Diseases like malaria, cholera, hepatitis, yellow fever, or West Nile virus and other viral diseases present increasing health threats to large populations in the world, with major existing problems at the stage of proper diagnosis.  The Company believes that it can adapt its VT-1000 Desktop Analyzer and SPARKS Mobile to the rapid, simple, point-of-care diagnosis of almost all of these diseases without the requirement of additional equipment. Further, the Company believes that the combination of a mobile, hand-held testing device with a large number of different tests provided by a family of cartridges will improve the ability of current healthcare and disease diagnostics in a fast majority of today’s underserved regions. In addition, the Target System Platform also allows for the monitoring of environmental components influencing the health of populations, such as the presence of toxins in soil and drinking water and contamination of food supply.

 

The Target System Hand-Held Analyzer: SPARKS Mobile

 

The Company’s next generation Target System Analyzer, the SPARKS Mobile, a hand-held analyzer, will include a small, rapid testing format, in conjunction with a hand-held data acquisition and test reading device. The SPARKS Mobile will be a re-engineered version of the Company’s previously FDA-approved VT-1000 Desktop Analyzer.

 

Whether searching for markers in the blood stream, or diagnosing a pathogen in urine, the Company’s SPARKS Mobile will be a portable tool for rapid diagnostics. The SPARKS Mobile will also provide an improvement in POC diagnostics and applications in countries with limited healthcare infrastructures and geographic limitations, both of which are of paramount importance in the combat against infectious diseases and in the fight against proliferation of endemic and pandemic diseases.  This innovative SPARKS Mobile will allow for a fast (minutes instead of hours or days) performance of tests at the point-of-care and will only require a test cartridge and a small number of ready-to-use solutions in preformatted quantities.  Moreover, the SPARKS Mobile will include the ability to store patient information, test data, and QC data, and transmit data through wireless connections.

 

The SPARKS Mobile design goals will plan to:

 

achieve a portable monitoring system, which is compatible with proven and reliable ELISA-based target system technology. 

expand readout capabilities to provide a mobile testing and monitoring platform. 

increase the economy of scale and scope of the diagnostics and monitoring platform by the development of additional utility of the device without redundant infrastructure investments (additional data acquisition of patients, additional tests for other, predominant diseases). 

 

The basic design of the Company’s SPARKS Mobile is based on the same 510(k) cleared technology employed in its VT-1000 Desktop Analyzer and is compatible with existing Test Cartridges. However, a number of innovative features will be integrated into the design to meet customer and patient needs:

 

High Infrared Light Spectrum.  

Easy Field Upgrades 

No Change of Equipment  

Printer Hook-up Capability  

Low Entry Cost for New Test Development and Analysis  

Safety, Security and Accuracy by design 

Desk to Docking Station: Smart Phone Capability  


Table of Contents

- 7 -



Market Opportunities

 

In recent years, there has been a continuing shift from the use of laboratory-based analyzers to more technologically advanced point-of-care tests that can be performed in a matter of minutes. Unlike the centralized clinical laboratory segment, which is mature and highly competitive, the point-of-care market is still a relatively early stage market. Although certain simple single analyte diagnostic tests have been developed, such tests have remained incapable of precise and highly sensitive quantitative measurements. As a result, medical tests that require precise quantization of the target analyte have remained the domain of immunoassay analyzers.

 

Diagnostic tests performed outside the central laboratory or decentralized testing is generally known as point-of-care (POC). Over the years, the increasing introduction of transportable, portable, and handheld instruments has resulted in the migration of POC testing from the hospital environment to a range of medical environments including the workplace, home, disaster care and most recently, convenience clinics. Moreover, POC test devices have contributed significantly to the growth of the overall diagnostics market over the past 10 years. As more diagnostic manufacturers pursue CLIA waiver status for their POC devices and CE Mark for POC or self-use. At the same time, more decentralized test venues invest in non-waived rapid tests and instruments. POC testing appears to be headed for an even bigger role in diagnosis and monitoring patient care.

 

The Global In-Vitro Diagnostics market is expected to grow to $69.1 billion by 2017, up from $49.2 billion in 2012. The growth represents a 7% compounded annual growth rate in five years. Self-testing is the biggest trend fueling the growth. The self-testing market is poised to grow at a CAGR of 9.3% from 2013 to 2018, to reach $27.5 billion by 2018. The growth is being driven by devices aimed at making acute care more efficient. There is a concerted effort to reduce time spent in expensive intensive care units and in the hospital in general. More tests and technologies have been adapted to serve the needs of physician offices and home testing.

 

Key Drivers

 

The two factors that are significant to the rapid growth of POC testing are technology advancements and healthcare economics. The development of new and improved technologies has resulted in the ability to make evidence-based medical decisions that improve patient outcomes and reduce patient acuity, criticality, morbidity and mortality.  Quicker diagnosis of infectious agents can also permit the earlier prescription of appropriate medications, thereby potentially shortening the duration of illness.  Additionally, the economic climate is driving significant changes in the manner in which patients will be tested and how results are delivered. Recent revisions to government regulations, together with growing patient and insurer pressures on hospitals and physicians have increased incentives to reduce overall patient healthcare costs while providing a higher level of care to a greater number of patients. One cost-cutting measure is to reduce the high cost of diagnostic testing carried out in central laboratory sites.

 

Limitations

 

Each of the screening devices described above have limitations in their utility and range of application. Many screening devices have been adopted from their use in clinical laboratories and, when applied to POC application, required special handling of the specimen samples (blood, urine, and feces) and decreased sensitivity and/or specificity.

 

Competitive Landscape

 

There are approximately 40 to 50 companies in the point-of care (“POC”) diagnostic industry in the U.S. and approximately another 100 outside the U.S. The POC space can be broken down into various sub-sets such as molecular biologist developing reagents, and markers to diagnostic equipment and test development companies, as well as companies who do neither and focus on marketing tests, equipment and assays.  Most notably in the POC space are the large pharmaceutical companies such as Bayer, Roche, Abbott Labs, ThermoFisher and others.  The Company’s specific competitive landscape is tied to its patent pending process involving its SPARKS Mobile Analyzer and Target System Platform In-Vitro Tests.  There are a number of companies developing mobile devices to perform a host of health industry-related services and the Company believes that more companies will enter the mobile diagnostic space in the next few years.  The industry has yet to develop a standardized point-of-care immunoassay platform for any device to be integrated into.  The goal of the Company’s SPARKS Mobile Analyzer is to deliver a device that adds immediate value to health providers, patients and health insurance companies.  The Company’s primary goal is to create a mobile platform that could integrate and utilize the flow-through process of the Company’s Target System Platform and offer the healthcare provider a system that is fully interoperable and ubiquitous with a potentially large number of in vitro tests.  There are other test platforms in the space, but the Company has filed a patent on the process of its SPARKS Mobile Analyzer and its TADS Cartridge.  There can be no assurance that the Company’s POC device will prove to be competitive with the other POC devices under development.

 

Until the Company secures a minimum of three million dollars ($3,000,000) of additional capital to operate for the next eighteen months the Company will remain highly vulnerable from the Company’s competition.  The Company anticipates the need for a minimum of an additional six million ($6,000,000) dollars of investment capital will be required for it to achieve its goal of developing a commercially viable rapid point-of-care CD4-8 immune status test and its proposed mobile SPARKS Mobile version of its FDA Approved VT 1000 Desktop Analyzer.  There can be no assurance that such amount will prove adequate to develop the Company’ products. Furthermore, the Company’s competition has significantly greater resources that it can deploy and anytime to head off competition.

 

In Vitro Diagnostic Sales Leaders

 

Roche Diagnostics, Switzerland www.roche.com  

Abbott Diagnostics, Abbott Park, IL 60064 www.abbott.com  

Siemens Medical Solutions Diagnostics, Deerfield, IL www.diagnostics.siemens.com  

Johnson & Johnson, Ortho Clinical Diagnostics (OCD) division, Raritan, NJ www.jnj.com  

Beckman Coulter Inc., Fullerton, CA www.beckmancoulter.com  

Becton, Dickinson & Co., Franklin Lakes, NJ www.bd.com  

bioMérieux SA, Marcy l’Etoile, France www.biomerieux.com  

Bio-Rad Laboratories Inc., Hercules, CA www.bio-rad.com  

Quidel Inc., San Diego, CA www.quidel.com 

Alere, Inc. Orlando, FL www.alere.com 

Thermo Fisher Scientific, Waltham, MA www.thermofisher.com 


- 8 -



Barriers to Use

 

The main barriers and constraints to the use of rapid diagnostic tests can be put into three main categories:  

 

Acceptability:Rapid tests need to be acceptable to policymakers, clinicians, and patients. Tests need to have sufficient sensitivity and specificity and need to have an adequate predictive value. Ease-of-use is critical for point-of-care use by clinicians. Culturally appropriate specimens and credible results are important if rapid tests are to be accepted by patients. 

 

Affordability:Many rapid diagnostic tests are more expensive than the tests or syndromic algorithms they are intended to replace. Decreasing per-test costs, carefully designing diagnostic algorithms, and educating end users about the cost-savings of more efficient use of therapeutic drugs are important means of maximizing rapid test affordability. 

 

Availability:Rapid diagnostic tests are not always available in developing countries. Most tests have limited shelf lives, and many countries have weak public and private sector procurement and distribution systems. The consistency and quality of imported tests can also be issues. To address these constraints, local government regulations, quality assurance, shelf life testing, and distribution systems all need to be assessed and improved. The Company will initially control all of the manufacturing of its Target System test cartridges and Desk Top Analyzer and SPARKS Mobile Analyzer in conjunction with Montecito. 

 

Reimbursement:The ability to gain scale in reimbursement across a wide number of tests is still a challenge for point of care diagnostic companies such as Parallax.  

 

Intellectual Property (Diagnostics)

 

The Company’s products include a previously FDA-cleared VT-1000 Desktop Analyzer and more than a dozen previously FDA 510(k)-cleared tests.  The Company acquired the exclusive rights in perpetuity to a number of pending USPTO Patent Applications on the Company’s products in the area of Infectious Diseases, as well as methods for future test development, through a License Agreement with Montecito BioSciences, Ltd.  Parallax intends to seek Intellectual Property protection for all supporting products such as novel biomarker candidates, antibodies, proteins, and diagnostic tests surrounding the Company’s core indication areas, in order to create a barrier to entry for its competitors.

 

Expired Patents-Target System

 

The Target System and certain of its related components were previously issued patents by the United States Patent and Trademark Office (“USPTO”).  The following previously-issued patents have expired:  

 

USPTO Patent #

Description

Date Filed in US

Date Expired

US4,748,042

Target Ringing & Spotting Machine (method and Apparatus for Imprinting membrane with pattern of antibody)

May 31, 1988

May 31, 2008

US4,797,260

Target Cassette (Antibody testing system)

January 10, 1989

January 1, 2009

US5,137,691

Target Cassette with Removable Air Gap (Antibody testing system with removable air gap)

August 11, 1992

August 11, 2012

 

The Company has retained a team of professionals in the field of patent protection and is continuously seeking out new opportunities for its products and products in development.

 

Key Patented and Patent-Pending Concepts

 

Sample Analysis 

Plurality of Isolated Antibodies to a Plurality of Cognate Antigens 

Identifying Drugs, Targeting Moieties or Diagnostics 

Determining the Immune Status of a Subject  

Flow Through Testing System with Pressure Indicator 

Novel biomarker candidates 

Antibodies 

Proteins 

Diagnostic testing 

 

For additional information on the Company’s patents, patents-pending and Tests, see “INTELLECTUAL PROPERTY SUMMARY” section below.

 

The Company’s FDA-Cleared Tests

 

The Company acquired, through an Assignment Agreement, the exclusive rights in perpetuity to the following FDA-approved 510(k) tests (the “Tests”):

 

No.

Test/Device Name

510(k) Number

 

No.

Test/Device Name

510(k) Number

1

Rotacube (Rotavirus)

K884017

 

14

First Sign (Pregnancy, Hcg)

K973208

2

Rubella-Cube TM

K892051

 

15

Target Hcg

K914303

3

Cmv-Cube TM

K884842

 

16

Target Quantitative Hog One Step

K903937

4

Target Quantitative Hcg

K890131

 

17

V-Trend Target Rf Test

K904105

5

Target Strep A (Streptococcus Spp.)

K880460

 

18

Blue Dot Test for Pregnancy

K884017

6

V-Trend Target Im Test (infect mononucleosis)

K890041

 

19

Target Cocaine Metabolites-R Test

K910122

7

Target Reader

K885254

 

20

Target Cocaine Metabolites-V Test

K910123

8

Target Cardiac Ck-Mb

K890295

 

21

Target Cannabinoids-R Test

K910893

9

Target Cardiac Troponin 1

K972094

 

22

Target Cannabinoids-V Test

K910892

10

Target C-Reactive Protein Test

K892231

 

23

Target Amphetamines/Methamphetamines-R Test

K910739

11

Target C-Reactive Protein Test

K890423

 

24

Target Amphetamines/Methamphetamines-V Test

K910740

12

Target Myoglobin

K963680

 

25

Target Opiate-R Test

K890978

13

Target Aso Test

K910073

 

26

Target Opiate-V Test

K890979

 

The Company is in the planning process of developing and obtaining FDA clearance for rapid Immunoassay tests for the detection of HIV 1 and 2.  There can be no assurance that the Company will be successful in developing such tests or in obtaining the required FDA clearance.


Table of Contents

- 9 -



For further information on the exclusive rights to these Tests, and the complete text of the Assignment Agreement and subsequent Modification, please refer to Exhibits 10.19 and 10.21, respectively, to the Company’s Current Report filed November 15, 2012 on Form 8-K.

 

It is expected that after successful re-introduction of the Target System and the introduction of its novel PROMISE CD4 immune status test, additional tests will be developed and protected by the Company. Generally, the Company and Montecito BioSciences, Ltd. will own improvements to the basic technology platform in exclusivity.

 

Government Regulations

 

The long legal journey toward medical device regulation began with the Pure Food and Drugs Act of 1906.  Medical devices were not included, as no one envisioned how technology would grow increasingly complex, and would ultimately require regulation. The Medical Device Amendments of 1976 gave FDA authority to ensure the safety and effectiveness of a range of life-saving medical devices, while also protecting the public from fraudulent devices.  The Amendments:

 

defined a medical device, 

established three device classes (I, II, and III), 

identified pathways to market, 

established Advisory Panels, and 

set clinical investigation requirements. 

 

Subsequent legislation strengthened the FDA’s regulatory authority.  The following table identifies the legislation and significance for the Major Medical Device:  

 

Legislation

Significance

Safe Medical Devices Act of 1990

Established Quality System requirements 

 

Supported post market surveillance 

 

Allowed FDA discretion for PMAs brought to panel 

FDA Modernization Act of 1997

Supported for early collaboration, expanded Class I and Class II exemptions 

 

Set the "least burdensome provision"* 

 

Supported dispute resolution 

 

Established evaluation of automatic Class III designation (giving the sponsor the opportunity to  

request lower classification due to a minimal risk device, known as "de novo" review)

 

Mandated free and open participation by all interested persons 

Medical Device User Fee and Modernization Act (MDUFMA) of 2002

Established a fee schedule for most types of device submissions to achieve shorter review times 

 

Requires FDA to include pediatric experts on the panel for a product intended for pediatric use 

FDA Modernization Act of 2007

Reauthorized and expanded MDUFMA 

 

The least burdensome provision allows industry and FDA to consider the least burdensome appropriate means of evaluating a device’s effectiveness when there is a reasonable likelihood of its approval. The intent is to help expedite the availability of new device technologies without compromising scientific integrity in the decision-making process or FDA's ability to protect the public health. This provision does not lower the standard for premarket clearance.

 

Premarket Approval (PMA)

 

PMA refers to the scientific and regulatory review necessary to evaluate the safety and effectiveness of Class III devices or devices that were found not substantially equivalent to a Class I or II predicate through the 510(k) processes.  PMA is the most involved process. To reasonably assure that a device is safe and effective, PMA requires valid scientific evidence that the probable benefits to health from the intended use of a device outweigh the probable risks, and that the device will significantly help a large portion of the target population. Sources of valid scientific evidence may include well controlled investigations, partially controlled studies, historical controls, well documented case histories by qualified experts, and robust human experience.  Independence is an important concept for PMAs, meaning that each PMA should establish the safety and effectiveness of the device under review, and that data about one device cannot be used to support another.  Examples of PMAs include digital mammography, minimally invasive and non-invasive glucose testing devices, implanted defibrillators, and implantable middle ear devices.

 

Summary Comparison of 510(k) and PMA

 

510(k) Submissions

PMA Submissions

primarily for Class II devices 

primarily for Class III devices 

a Class I or II pre-amendment or legally marketed device (predicate) exists 

a Class I or II pre-amendment or legally marketed device (predicate) does not exist 

third party review option is available for devices not requiring clinical data 

device is life supporting and/or has potential risk to patient 

documented proof of Substantial Equivalence to a predicate is required 

documented safety and effectiveness data for the device is required 

 

Post-Approval Studies

 

The FDA can impose requirements at the time of approval of a PMA or HDE, or by regulation afterwards. One requirement may be the need for post-approval studies. The CDRH Post-Approval Studies Program helps ensure that well designed post-approval studies are conducted effectively and efficiently and in the least burdensome manner. Post-approval studies should not be used to evaluate unresolved premarket issues that are important to the initial establishment of device safety and effectiveness.

 

With post-approval studies, FDA can evaluate device performance and potential problems when the device is used more widely than in clinical trials and over a longer period of time. This allows FDA to build in accountability and gather essential post market information, including: 

 

longer-term performance of the device (for example, effects of re-treatments and product changes) 

community performance (clinicians and patients) 

effectiveness of training programs 

sub-group performance 

outcomes of concern – real and potential 


- 10 -



Manufacturing

 

The Company does not intend to manufacture in house, with the exception of prototype and small batch production of tests for clinical trials and in-house testing.  The Company is required to use manufacturers who operate under Good Manufacturing Practices (“GMP”).  A GMP is a production and testing practice that helps to ensure a quality product. Many countries have legislated that pharmaceutical and medical device companies must follow GMP procedures, and have created their own GMP guidelines that correspond with their legislation. Basic concepts of all of these guidelines remain more or less similar to the ultimate goals of safeguarding the health of the patient as well as producing good quality medicine, medical devices or active pharmaceutical products. In the U.S. a drug may be deemed adulterated if it has passed all of the specifications tests but is found to be manufactured in a condition which violates current good manufacturing practice guidelines. Therefore, complying with GMP is a mandatory aspect in pharmaceutical manufacturing.

 

Although there are a number of them, all guidelines follow a few basic principles:

 

Manufacturing processes are clearly defined and controlled. All critical processes are validated to ensure consistency and compliance with specifications. 

Manufacturing processes are controlled, and any changes to the process are evaluated. Changes that have an impact on the quality of the drug are validated as necessary. 

Instructions and procedures are written in clear and unambiguous language. (Good Documentation Practices) 

Operators are trained to carry out and document procedures. 

Records are made, manually or by instruments, during manufacture that demonstrate that all the steps required by the defined procedures and instructions were in fact taken and that the quantity and quality of the drug was as expected. Deviations are investigated and documented. 

Records of manufacture (including distribution) that enable the complete history of a batch to be traced are retained in a comprehensible and accessible form. 

The distribution of the drugs minimizes any risk to their quality. 

A system is available for recalling any batch of drug from sale or supply. 

Complaints about marketed drugs are examined, the causes of quality defects are investigated, and appropriate measures are taken with respect to the defective drugs and to prevent recurrence. 

GMP guidelines are not prescriptive instructions on how to manufacture products. They are a series of general principles that must be observed during manufacturing. When a company is setting up its quality program and manufacturing process, there may be many ways it can fulfill GMP requirements. It is the company's responsibility to determine the most effective and efficient quality process. 

 

Distribution

 

The Company has not yet commenced commercial operations, and thus it has yet to develop methods of distribution for its products beyond the business plan stage.

 

In order to commercially sell the Company’s VT-1000 Desktop Analyzer, the Company must have it manufactured under GMP.  The Company can and will provide demonstrations of its VT-1000 Desktop Analyzer capabilities to potential customers.

 

The Company will need to secure additional capitalization before it can acquire additional antibody markers, produce additional Target System cartridges or produce its VT-1000 Desktop Analyzer under GMP.

 

Principal Suppliers

 

The Company has not yet commenced commercial operations, and thus has yet to establish principal suppliers of its product line.

 

 

ROXSAN PHARMACY, INC.

COMPOUND and RETAIL PHARMACY SERVICES

 

Overview

 

RoxSan Pharmacy, Inc. ("RoxSan”), was incorporated on February 16, 1996, in the state of California, and is located in Beverly Hills, California. Prior to its incorporation in 1996, RoxSan was a privately-owned company providing pharmacy services since the early 1960s.

 

RoxSan is the oldest continuingly operated pharmacy in Beverly Hills and is a well-known commodity to the residents, providing retail, compound, infertility, wellness, anti-aging and sexual health products and services for over 60 years.

 

RoxSan’s mission is to deliver innovative, meaningful personalized medicines to patients by providing healthcare professionals cutting edge tools to leverage their knowledge and individualize patients’ treatment plans. RoxSan’s favorable pricing is competitive with other pharmacies that provide compounding services, but RoxSan exceptional customer care is what has proven to be the key to its success and longevity.  RoxSan caters individually to patients through customized products, speedy home delivery, and having an on-call readily accessible pharmacy team. RoxSan can also educate its medical providers through scheduled seminars with its pharmacists.  In addition, RoxSan’s parent company owns a Remote Health Monitoring company that can provide doctors and patients with live, interactive healthcare through its monitoring devices (see section entitled Parallax Health Management, Inc.).

 

RoxSan is a full-service retail, sterile and non-sterile compounding and fertility pharmacy licensed in the State of California and over 40 other states, and is VPP Certified (see National Accreditation). RoxSan not only provides commercial pharmaceuticals to its patients, but also specializes in customized compounded medications for individual patient needs based on prescriber recommendations. RoxSan’s current area of expertise includes pain management with a focus on non-addictive compounded topical pain creams, wound care, scar healing, and podiatry care compounds.

 

RoxSan generates net revenues primarily by dispensing prescription drugs, through local channels by direct delivery as well as mail order. RoxSan also sells a wide assortment of general merchandise, including over-the-counter drugs, beauty and cosmetic products, seasonal merchandise and convenience foods. Management developed a system of operations for RoxSan that focused on differentiating unique business markets for its services and developed additional areas of focus.  


Table of Contents

- 11 -



Shortly after RoxSan's acquisition in August 2015, management determined that there were several areas that required immediate attention:

 

Pharmacy Compliance

Management created the position of Director of Compliance at RoxSan and put a senior pharmacist as the Director.  Management developed a strategic plan covering its Regulatory Compliance goals.  The first goal was to create foundational standard operating procedures in the filling, processing, and shipping of prescriptions.

 

Under this program an audit report ("Audit Report") was discovered that was previously discarded by the prior ownership as having “no relevance” as to the results of the findings in that audit. This audit was part of a due diligence requirement imposed by the Company upon the prior owner before the acquisition, which was to have a third-party organization verify that the pharmacy was operating within compliance of state regulatory demands. The Audit Report dated prior to the acquisition, which was discovered in abandoned files, indicated that several areas of operation of the pharmacy were in violation of the most fundamental compliance rules, and strict warnings as to the consequences of what would happen to the pharmacy’s licenses if these areas were not immediately corrected. The Seller did not provide this “material” information while in due diligence prior to the acquisition. All areas recommended in the Audit Report to be corrected, were in fact implemented by the current ownership.

 

State Pharmacy Licenses

The former owner had developed a well-documented contentious relationship with the California Board of Pharmacy as well as a number of other states in which the previous owner was accused of regulatory violations. There were also states that had suspended RoxSan’s Licenses under the prior ownership to operate in their state.  The new management began an aggressive program in each state, to appeal to the State Pharmacy Boards to reinstate the licenses. It became apparent that many individual members on several state Boards of Pharmacy, including the California Board of Pharmacy, the Nevada Board of Pharmacy and the Arizona Board of Pharmacy, had an extremely negative perception of the former owner.

 

With the new management entering into the picture, the negative perception became extremely positive toward RoxSan’s new ownership, and its new Compliance Program.  Thus far, RoxSan has obtained pharmacy licenses in over 40 US states and is seeking to obtain licensing in the remaining states.  As a result of the efforts of new management, all of these issues were corrected, and the pharmacy is currently operating in an entirely new status of having great relations with each of the previously strained relationships with individual state Boards of Pharmacy.

 

Pharmacy Benefit Management

The former owner had created a negative and challenging relationship with Payers and Pharmacy Benefit Management (“PBM”) as well as the cancellation of some pharmacy network contracts with PBM contracts that control the approvals for reimbursements for several health insurers.  The new management established a plan of action and standard operating procedures to follow as well as address the criteria for contract re-approvals with the PBMs.  

 

RoxSan Pharmacy has become qualified and fully accredited member of FocusScript’s Compounding Pharmacy Network enabling RoxSan to participate in the Pharmacy Benefit Management Program for one of the largest health insurers in the United States.  As of this update approximately 5% of the Compound Pharmacy’s in the US have been able to achieve this accreditation.

 

A market development has occurred that has produced a payer reaction to the exorbitantly high pricing trends for compound pain medications. That development has affected the viability of the compound pain medication management industry due to rejections and many of the ingredients becoming “non-covered”. RoxSan has developed a program to restructure the pharmacy’s approach to creating a more “ethically” based pricing structure with extraordinarily high efficacy formularies and is working with several of the industry’s leading PBMs in pursuit of partnership arrangements.

 

National Accreditation

In addition, under the new management, RoxSan Pharmacy passed the inspection from the Verified Pharmacy Program (VPP) as part of the National Association of the Board of Pharmacy.  This was a significant accomplishment, considering that the prior ownership had failed in passing the VPP inspection in the past. Passing the VPP inspection is an exhaustive process requiring high levels of regulatory systems and compliance.  This accomplishment was achieved in less than one year under the newly restructured operating compliance program under the new ownership, which included strict adherence to documentation retention and categorization.

 

Human Resources

It was determined that there were personnel issues that RoxSan’s pharmacists, technicians and general operations employees had with the prior ownership. These issues involved compensation, benefits and management style of leadership, which lacked the opportunity for the employees to be empowered to effectively perform their duties. Management also addressed these issues with clarification of job responsibilities, compensation/benefit adjustments including stock option incentives and an overall more inclusive and open communication style of management.

 

Closure of RoxSan Pharmacy

 

Since the Company’s acquisition of RoxSan, the deleterious actions against the pharmacy by the former owner, including, among other things, interference with management and operations, and attempts to damage and/or divert customer and vendor relationships, had a significant adverse impact on the pharmacy. Furthermore, the discovery of the former owner’s alleged involvement in suspected insurance fraud caused RoxSan’s contract with its primary IVF drug rebate program to be terminated in August 2016. As a result, RoxSan was no longer eligible to receive incentive rebates for the majority of its IVF drug purchases, which were key to the profitability of the IVF drug sales; and for which without the rebates, RoxSan was unable to provide its customers with comparably priced IVF drugs.  This, among other things, caused a precipitous drop in RoxSan’s IVF revenues, and ultimate exit from the IVF market in mid-2017.  Soon thereafter, in July 2017, RoxSan’s contract with its primary drug supplier was terminated for similar reasons connected to the former owner and alleged criminal activities associated with the Melamed family name, despite the Company’s new ownership and management. After careful consideration, the Company determined that RoxSan was unable to generate enough profits to sustain its pharmacy business, and in December 2017, the pharmacy ceased operations.

 

On May 14, 2018, pursuant to a unanimous resolution of the Boards of Directors of RoxSan Pharmacy, Inc. and Parallax Health Sciences, Inc., RoxSan filed a Chapter 7 petition in the United States Bankruptcy Court for the Central District of California.  Mr. Timothy Yoo was appointed trustee on May 15, 2018.  In connection with this filing, RoxSan seeks to discharge approximately $5 million of liabilities owed to various parties including more than $1 million owed to the Company.


- 12 -



PARALLAX HEALTH MANAGEMENT, INC.

REMOTE PATIENT CARE - GOOD HEALTH OUTCOMES PLATFORM

 

Overview

 

Parallax Health Management, Inc. (“PHM”) is a wholly-owned subsidiary of the Company and is part of the Company’s overall healthcare strategy.  PHM is a systems integrations operation that provides remote patient monitoring (“RPM”), medication adherence and intelligent tele-medicine delivery systems featuring industry-first capture and data analysis capabilities.  

 

PHM’S primary goal is to deliver good health outcomes for patients through a service that allows healthcare providers of all types to reduce costs, increase revenues and provide a better patient experience and satisfaction. PHM’s Good Health Outcomes platform is promoted through its direct relationships with hospitals and accredited nursing operations, as well as health and wellness service providers, looking to adopt and integrate RPM and telehealth service models within their product and service offerings.

 

PHM integrates remote monitoring solutions that promote patients’ compliance to therapy, pharmaceutical and treatment regimens prescribed by their physician.  Alerts and notifications are used through the platform, and include a series of visual, audible and vibration prompts for patient through email and SMS, and Cloud-based recording for caregivers, for continuous patient monitoring and telehealth delivery capabilities.

 

PHM’s systems also offer the automation of dispensing packaged medications through a patented process, which can reduce the non-compliance costs and risks for medication, therapy and treatment; and can increase the financial and service delivery success and yields for healthcare providers, ultimately increasing the quality of life for the patient, doctors and care providers, and providing peace of mind for all.

 

Remote Patient Care

 

PHM’s Good Health Outcomes platform features a full set of modern communications technologies specifically targeted for patients that securely ensures data security compliance as well as real-time voice and “video conference” communication directly from any mobile or Internet-connected device. The platform, combined with systems integration services that interface with Electronic Health Records (“EHR") and Electronic Medical Records (“EMR”) technology platforms, enables “virtual doctor visits,” increasing the conveniences for both patients and their doctors and care providers.  PHM’s Good Health Outcomes platform and its systems integration positioning, allows for any physician, clinician, nurse, pharmacist, caregiver or family member in a persistently connected real-time system, to support the treatment of the chronically ill, acute and post-acute on a greater scale and with greater precision, outcome and patient satisfaction.  

 

In a residential environment, RPM benefits are equally important. Seniors and the chronically ill are germane as residents that require less support, less intervention, higher resident-participation rates, increased cognitive capability, overall increased health, a more assured client family environment, longer client stay-times, overall better client health and a more value-added contribution of staff members (and resultant staff satisfaction).The ability to remotely monitor each client, both from the point of view of their medication compliance and from connected sensors, that include everything from vitals monitoring and connected fall detection devices, to quality of sleep devices, enables the residential caregiver to provide a significantly enhanced (and commercially desirable) service for optimal health conditions.  With the adoption of a centralized monitoring system, residences will also begin to see a marked reduction in the inter-dependencies that can exist between residents, and an improved state of health- for every resident, further reducing the support load on staff members.  

 

Medication Monitoring/Compliance/Adherence

 

Nonadherence with medication is a complex and multidimensional healthcare problem. Patients forget to take their medications, creatively alter their medications, engage in unendorsed polypharmacy, mix their medications, and take medications in combinations that may have dire synergistic interaction effects, such as dizziness and confusion.  Estimates of medication nonadherence rates typically range from 20% to 85%, (see figure below). As a result, a substantial number of patients do not benefit optimally from pharmacotherapy and can wind up in emergency situations, hospitalized, or worse. In fact, hospital readmission generated by medical non-compliance and non-adherence was a $24 billion-dollar problem in the United States in prior years and is growing.

 

Picture 46 

 

Medication adherence is a cornerstone of significantly improved quality of life and the Good Health Outcomes platform is the cornerstone of medication adherence. A unique device specifically designed for seniors and the chronically ill, the Good Health Outcomes platform offers enormous potential for patients, their families, their caregivers and for those residences that choose to offer superior services and a superior health environment for their clients.

 

The Good Health Outcomes platform monitors the adherence of treatment and therapy regimens. In addition, with the advent of an intelligent personal medication device with bio-feedback allows, for the very first time, the quantitative and qualitative feedback of real-time data to pharmacists, physicians and clinicians and, based on the individual patient, enables medication titration to achieve optimal medication therapy.

 

PHM’s sister Company, Parallax Diagnostics, is in the development stage of acquiring, licensing and developing in-house solutions/products for personalized health monitoring of seniors that will capture a host of vitals. All of these sensor products can be connected to the Good Health Outcomes Hub so that this bio-feedback information is directly correlated with medication consumption information providing clinicians, pharmacists and physicians with real-time, comprehensive data and information on patient condition.


Table of Contents

- 13 -



Product Strategy

 

PHM’s product strategy is to eliminate obstructions to consumer adoption of remote patient care systems, so patients can stay out of the hospital longer and have a better quality of care and quality of life.

 

Remote patient monitoring systems enable efficient healthcare delivery to patients outside conventional hospital or clinical settings, by transmitting real-time patient data for remote clinical review. Correlating vitals with medication history and consumption directly informs healthcare providers as to the real-time status of a patient, at home or in residence. Anomalies can be reported or alerted to those in need, via the cloud. RPM systems incorporate wireless medical devices and computer-based software applications. The evolution of IoT and IoS technologies is clear and will offer significant business opportunities for patients, residences and the healthcare system in general. RPM is a cost-effective means of keeping patients out of the hospital and have a better quality of care.

 

Product Benefits

 

RPM systems, even within the walls of a single building, can offer countless benefits for the overall health management of clients.  There are countless tangible benefits to medication adherence as well, including significant reductions in hospitalizations, enhanced quality of life and reductions in the effects of both overmedication and undermedication. Eliminating the distribution and administration of scheduled medications exonerates the residence from the liabilities associated with this task. Human error is all but eliminated. Corporate risks are significantly reduced in this activity and liability insurance premiums may be reduced as well.

 

Essentially, increasing medication adherence through automation, empowerment and monitoring improves patient outcomes and achieves benefits for all health system stakeholders:

 

Patients:

Patient Families:

Better quality of life 

Better visibility into the quality of life of the loved one 

Fewer hospital visits 

Fewer hospital visits – fewer interruptions into their work days 

Better outcomes 

Better outcomes 

Reduced travel and health costs 

Reduced travel costs 

Increased social interaction with family and friends 

Increased peace of mind – reduced stress and concern 

 

 

Residential Providers:

Healthcare Industry:

Better overall quality of life in the residence 

Government, insurance and other payers reduce spending 

Reduced risk and liability 

Patients who are more adherent with medication regimes use fewer health services 

Superior service 

Pharmaceutical companies increase profitability and deliver value beyond the pill 

Reduced labor costs 

Pharmacy retailers ensure repeat orders, increased fulfillment and enhance brand loyalty 

Increased revenues for enhanced services 

Physicians have the ability to become proactive, rather than reactive 

Superior reputation / higher desirability / increased ability to charge for core services 

Every 1% improvement in medication adherence results in $2 billion in savings to U.S. 

Healthcare professionals and providers deliver better care more efficiently at lower risk 

Healthcare system and a $4 billion revenue increase to pharmaceuticals 

 

Differentiation in the marketplace for early adopters 

 

Market Opportunities

 

The market demand for remote patient care (“RPC”) solutions is at an all-time high and continues to increase due to healthcare insurance reimbursement of the services delivered over RPC systems.  Further, the move from “fee-for-services” to outcomes-based payment structures have brought about the need for doctors and all other healthcare providers to increase the efficiency and to reduce the costs of care delivery to patients.  Clearly, as with the introduction of any new technology, there is a significant market differentiator for early adopters. Residences, assisted living facilities and long-term care facilities all exist in a competitive environment in which differentiation between them is based upon higher desirability, which amounts to higher profits for those who are able to offer more. Unlike other service businesses, residences have the ability to attract clients requiring services on a long-term basis.  Additional market opportunities exist around hospitals and their management’s needs surrounding the reduction and elimination of patient readmissions.  

 

The global RPM systems market draws immense focus due to strict governmental measures to cut down healthcare expenditure, and reduce hospital stays. Remote Patient Monitoring serves to minimize hospital readmissions, and reduces the load on physician time, and nursing staff, thus greatly reducing healthcare costs. A rapidly aging population vulnerable to chronic diseases, and a growing desire to live independent lives among the elderly are driving growth in the market. Given the rise in the number of insured patients covered under reforms such as the Affordable Care Act, coupled with stricter reimbursement norms, healthcare providers are under constant pressure to manage wider patient population at lower costs. With the healthcare industry migrating towards an outcome-driven effective healthcare system, remote patient monitoring technology stands optimally positioned for growth.

 

Encouraged by the widespread proliferation of high-speed Internet, and related services, adoption of RPM systems is witnessing strong demand. There is growing interest in IoT-driven healthcare services and wearable medical devices that feature sensors, actuators, and other mobile communication methods through which patient data can be continuously transmitted onto a Cloud-based platform. Healthcare providers are increasingly adopting cloud computing technologies, which not only offer cost benefits but also allow healthcare organizations to increase operational efficiency.

 

The global market for remote monitoring systems is projected to reach over $66 billion by 2020, driven by government measures to reduce healthcare spending against a backdrop widening healthcare budget deficit.  As stated by the new market research report on Remote Patient Monitoring Devices, North America represents the largest market worldwide, occupying close to 41% of the total market share, and expected to grow at an exponential CAGR of 21.34% during the forecast period. Asia-Pacific ranks as the fastest growing market with a CAGR of 13% over the forecast period. The growth in the region is driven by the increase in per capita healthcare spending and the need for a cost-effective and sustainable healthcare system and infrastructure capable of addressing the growing healthcare needs of an expanding population.

 

The lucrative reimbursement policy introduced by the government agencies promoting the use of telemedicine and virtual health services is driving the market in North America. The US and Canada are the major revenue contributors to the market in North America. Further, the increasing investments in research and development and technological innovations will help major players in the North American region occupy a larger market share over the next few years.


- 14 -



Barriers to Entry

 

Key issues challenging smooth growth in the market include high upfront costs of devices, lack of reimbursement and clarity on associated accountability, privacy concerns regarding transmitting sensitive patient data, and security issues of devices.

 

Despite the significant potential benefits to outcomes and patient satisfaction that may accrue through the leveraging of patient-generated health data (“PGHD”) in clinical care, data ownership remains a barrier to greater use of PGHD in some circumstances. Though the collection and use of PGHD is intuitive to experienced patients, inclusion of such data represents a shift in the way medicine has been practiced. Taking an active role in the collection and management of data about one’s health status increases patient activation, which is strongly related to better health outcomes in multiple conditions.

 

Patients’ and providers’ use of mobile health (mHealth) apps provide a framework for assessing the role mHealth can play in medicine and as a source of PGHD. Physicians use social media primarily for personal use (60%), though accessing healthcare news (21%), communicating with peers (18%), marketing the practice (11%), and communicating to patients (4%) are also practiced. Among physicians who choose not to use social media, concerns about patient privacy (52%), lack of time (51%), concerns about liability (42%), the belief that social media has little professional value (40%), and lack of familiarity (23%) are cited most frequently. In 2014, two-thirds of physicians surveyed reported using a mobile app to check medication interactions, diagnose a condition, access EHRs, check results, create clinical notes, and prescribe electronically, and more than a third of US physicians recommended their patients use health apps.

 

Questions related to provider licensure pose another potential barrier to the routine use of mHealth. When a patient has his or her radiograph read, many current US state laws require that it be read by a physician licensed in the state where the patient is located and had the radiograph. PGHD can raise special issues. For example, if a patient lives in New York and has an mHealth device that continues to monitor certain aspects of his or her health and the patient crosses three states and then travels into the EU, does the patient’s physician need to be licensed in each of the other three states and in the applicable country in the EU when the data is transmitted from that state or country in the EU? Within the United States, most states require that the out-of-state physician receive an unrestricted license in the state in which the initial patient interaction occurred.  Some states issue a telemedicine license to facilitate practice across state lines when the physician holds an unrestricted license in another state.  In the radiograph situation, the imaging physician is reading the radiograph at one point in time and billing for that service. With the monitoring of an individual’s health information continuously, the clinician may be being paid to manage the patient’s condition or his or her overall care.  The special privacy and confidentiality issues can raise important mHealth implications. It is important that vendors and healthcare systems coordinate their efforts to minimize these issues.

 

Competitive Landscape

 

Countless smaller companies around the world are innovating in this sector and are now offering everything from Bluetooth connected toothbrushes and bathroom scales (weight loss or gain is a key indicator of health and disease state) to “wearable’s” that capture everything from body temperature, pulse rates, respiratory rates and blood pressure monitoring to game-changing technologies such as non-invasive blood glucometers that sample blood sugar level several times per second – continuously – without requiring lancets and the drawing of blood samples.

 

Medical Clinics, on a global scale, are already adopting technologies that allow them to provide better healthcare to a wider population base.  Insurance companies and HMOs also continue to seek the highest quality healthcare with the highest return on investment by leveraging modern technologies to provide better care to a greater population base at lower cost.

 

There are a large number of companies offering some form of wireless and remote technologies, patient data processing applications and equipment, and electronic medical record data transfer equipment. Competitors supplying advanced patient monitoring and telehealth systems to hospitals are large, established healthcare companies, often working in conjunction with information technology (“IT”) companies on an entire system. The home healthcare and other sectors are much more fragmented and are dominated by privately held companies. In addition, some companies supply innovative products, but only for a small segment of the market; and some companies supply products on a regional basis only. 

 

There is a world-wide interest in “connected health” with major companies such as Philips, Nokia, Apple, IBM, Microsoft and Google, all investing heavily in sensors and sensor systems for healthcare, connectivity and RPM. Traditional telcos like AT&T, Verizon and a host of others are also investing heavily in healthcare systems and in the RPM market.

 

Major players in the global RPM market include Abbott Laboratories, Aerotel Medical Systems, AMD Global Telemedicine, Inc., BIOTRONIK SE & Co. KG, Boston Scientific Corporation, GE Healthcare Ltd., Honeywell Life Care Solutions, Intelesens Ltd., LifeWatch AG, Masimo Corporation, Medtronic Plc, Mindray North America, Nihon Kohden Corporation, Omron Healthcare, Inc., Philips Healthcare, Qualcomm Life, Inc., St. Jude Medical Inc., and Welch Allyn, Incorporated.

 

Intellectual Property (Remote Patient Care)

 

The Company, through an Assignment Agreements with La Frontera Community Solutions, Inc., acquired all worldwide rights, title and interest in and to the patent applications for the technology underlying the Good Health Outcomes platform and systems.

 

Key Patented and Patent-Pending Concepts

 

Diagnostic Monitoring 

Data Driven Outcomes  

Remote Patient Monitoring  

Remote Patient Biometrics  

Remote Patient Diagnostics  

Remote Medication Monitoring 

Remote Medication Delivery 

Remote Medication Reconciliation   

 

For more information on these patent applications, please see “INTELLECTUAL PROPERTY SUMMARY” section below.  


Table of Contents

- 15 -



Government Regulations

 

The FDA regulates certain medical devices and also certain mobile medical apps. On September 25, 2013, it issued a Final Guidance that defines “mobile medical app,” as a mobile app that (1) meets the definition of a “device” in the Federal Food, Drug and Cosmetic Act and (2) is intended to be used as an accessory to a “regulated medical device’ or to transform a platform into a “regulated medical device.” The Guidance grouped mobile medical apps into three categories: 1) apps that are actively regulated, (e.g., a mobile medical app that monitors the patient’s blood glucose levels and calculates the amount of insulin needed based on the patient’s condition, age, weight, etc.); 2) apps that are subject to enforcement discretion, (e.g., a mobile medical app that provides a patient an alert as to when to take his or her medications); and 3) those that are not considered devices and thus are not regulated (e.g., a mobile medical app that merely provides general healthcare information available on the Internet, not directed to a specific patient).

 

The FDA guidance addresses data security because patients and other users may experience severe consequences should the device lack adequate data protection or be hacked. The guidance does not address the protection of privacy. Rather, privacy is protected by the Health Insurance Portability and Accountability Act (“HIPAA”), where applicable. When patients’ health information is in the possession of health providers, health plans, business associates, or other covered entities, it is protected under HIPAA; when it is transmitted among individuals or organizations that are not covered entities under HIPAA, it is not protected. Accordingly, health information transmitted via a mobile device by a covered entity is protected under HIPAA privacy and security rules. However, this same information transmitted via a non-covered entity under HIPAA is not protected. HIPAA also does not cover information on an individual’s mobile device.

 

Patient-generated health data (“PGHD”) is merely data of the patient if a patient checks their blood glucose levels with a mobile device. If, however, he or she uses the device to transmit that information to their clinician for the purpose of monitoring that person’s care and the information becomes part of the patient’s electronic health records (“EHR"), the PGHD then falls under HIPAA.

 

The Federal Trade Commission (“FTC”) is not hesitant to file complaints against companies that it believes fail to reasonably protect the security of consumers’ personal data, including medical information. In August 2013, FTC filed a complaint against LabMD, Inc., alleging that the medical testing laboratory exposed the personal medical information of more than 9,000 consumers by placing the information on a peer-to-peer file-sharing network. The filing followed the discovery of the personal information of several hundred consumers who used LabMD’s services in the possession of identity thieves. In this case, as in an earlier case against a medical transcription firm that exposed personal medical information on the public Internet, FTC is acting to enforce HIPAA’s security requirements.

 

FTC also regulates misleading claims. If in the sale or distribution of a mobile medical app or device one makes claims about what the device can do, FTC can bring an action to make the individual or entity cease and desist from making such claims. In 2013, FTC published a written guidance and a short video for mobile app developers that offer advice on creating apps that protect users’ privacy and comply with truth-in-advertising principles.

 

Principal Suppliers

 

As of December 31, 2017, the principal suppliers of the medical devices utilized with the Good Health Outcomes platform were:

 

Amazon Web Services, Seattle, WA 

HIPAA-compliant secure server environments for hosting and management of GHOP and Compass.

La Frontera’s Empact Suicide Prevention Center, Tempe, AZ 

Largest CARF certified behavioral health suicide prevention call center in United States.

Royal Phillips, Inc. 1070 MX Amsterdam, The Netherlands 

Primary RPM software and hardware supplier; platform built upon Salesforce.com infrastructure providing clinical, monitoring center and patient management portals for mobile and desktop access.

 

The Company relies upon these suppliers to provide the majority of its delivery of its remote patient monitoring systems and services.  The services are web based and although the Company relies on these vendors, it can also hold them accountable, receive volume-based pricing, discounts and partnership advantages through the competition of its suppliers. Parallax has the ability to change vendors at any time in all service and product lines. Further, PHM is working towards the elimination of its reliance on software and hardware providers related to its in-home RPM offerings and services.

 

PARALLAX BEHAVIORAL HEALTH, INC.

PATENTED INTRINSIC CODE TECHNOLOGY

 

Overview

 

Headquartered in Santa Monica, California, Parallax Behavioral Health, Inc. (“PBH”) is a Delaware corporation providing consulting and software solutions to businesses and individuals to improve value, margin, and performance though enhanced outcomes and reduced costs.

 

On April 26, 2017, PBH completed the acquisition of 100% of certain intellectual property from ProEventa Inc., a Virginia Corporation (“ProEventa”), in accordance with the Intellectual Property Purchase Agreement between the Company, PBH and ProEventa (the “ProEventa Agreement”). ProEventa has an expertise in the development of behavioral health technologies, and is the wholly-owned subsidiary of Grafton Integrated Health Network, Inc., a non-profit Virginia corporation (“Grafton”), Pursuant to the ProEventa Agreement, in exchange for 100% of that certain intellectual property, among other things, consideration to ProEventa included:

 

a stock purchase agreement to purchase 2,500,000 shares of the Company’s common stock; and 

a revenue sharing agreement, providing for a cash earn-out to be paid to the ProEventa shareholders of up to $3,000,000, to be derived from certain net revenue generated by the Company, as defined in the agreement; and 

a royalty agreement, providing for a royalty of 3% of the revenues generated from the intellectual property, ending at such time as Parallax has paid ProEventa $25,000,000; and 

a limited license to ProEventa for the use of certain of the Intellectual Property's technology at Grafton Schools. 

 

On April 26, 2017, in conjunction with the ProEventa Agreement, the Company entered into a consulting agreement with James Gaynor, founder of ProEventa, that, among other things, provides for consideration to Mr. Gaynor as follows:

 

a stock purchase agreement to purchase 500,000 shares of the Company’s common stock at $0.001 per share; and 

a grant of options to purchase 1,000,000 shares of the Company's common stock at a price of $0.25 per share, vesting annually over a three (3) year period beginning September 1, 2017. 

 

With the completion of this acquisition, the patented technology entitled “Platform for Optimizing Data Driven Outcomes,” is added to the Parallax patent portfolio.  


- 16 -



Product History

 

For over a decade, Grafton School, Inc. (“Grafton”), a Virginia corporation, perfected a manual system of outcomes developed by Dr. Lisa Marshall and James Gaynor, that re-invented utilizing cloud computing and the internet.  In March 2014, ProEventa, Inc. (a Latin word meaning, “Good Outcomes”), and wholly-owned subsidiary of Grafton, was formed, and began marketing the software based on rights granted by Grafton. originally named REBOOT (“REBOOT”), an acronym for Reliable Evidence-Based Outcomes Optimization Technology, REBOOT, the behavioral health platform, was developed to provide goal obtainment through mastery of skills in a customized and fully automated data analysis and intervention model.

 

The technology is supported by applied behavioral analytics and over 25 years of efficacy studies and reduction to practice at Grafton. combined with over $3.75 million-dollar invested to transition the system to a cloud-based platform with mobile applications.

 

PBH rebranded the technology in 2018, and the proprietary software is now known as the Intrinsic Code (“Intrinsic Code”).  PBH has licensed the improved technology platform for systems integration into the Company’s diagnostics and remote patient care systems.

 

Product Strategy

 

The patented feature set of the Intrinsic Code platform allows it to provide progressive-predictive analytics and goal optimization intelligence on concurrent and compounding goals for an individual or group of people. Its’ utility is broad and has use cases in many vertical growth markets.

 

The product strategy is to enter the market through the healthcare initiative of the Company’s remote patient care and diagnostics divisions. The integration of Intrinsic Code is a key differentiating advantage within the remote patient care market.  The software can be harnessed to assess and prioritize patient goals, provide interventions, track behavioral data and provide meaningful feedback toward goal obtainment, as well as real time decision support with robust progress reporting. The resulting decision support and patient support, combined with the remote patient care and diagnostics technologies, make for a technology advantage and an industry first feature set that is designed to take away market share from competitors and capture new client accounts in healthcare field focused on doctors, nursing operations, and hospitals.

 

The technology can be marketed through user licensing or enterprise licensing contracts within the healthcare market, in both platform and supported mobile applications, including the Parallax application known as Compass (‘Compass”).

 

PBH believes that healthcare organizations for the first time will have the opportunity to "scale" their patient adherence programs while having visibility into its effectiveness and bottom line impact. Individual users will have a goal wizard, virtual coach and rules engine that will help create a path toward wellness. With personalized analysis, decision support and "goal" mastery feedback, the individual will be primed, guided and motivated to adhere to their treatment plan.

 

PBH’s Intrinsic Code is also applicable to many vertical markets outside healthcare.  The short-term strategy is to monetize the patented technology in healthcare exclusively through PBH, and license to non-competitive companies within other market verticals. PBH is assessing and prioritizing the licensing prospects.  The management team is also monitoring and identifying patent infringement, and some, already identified, are being assessed for licensing value.

 

Behavioral Healthcare Industry

 

Per a Behavioral Health Services 2016 Report by Captstone Partners, the demand for behavioral health services will continue to grow due to increased awareness and affordability of mental health and substance abuse treatment options. According to the Substance Abuse and Mental Health Services Administration (“SAMHSA”), expenditures on mental health and substance abuse treatment are estimated to have reached $239 billion in 2014. By comparison, expenditures only totaled $42 billion in 1986 and $121 billion in 2003. More specifically, revenues generated by the substance abuse treatment industry reached an estimated $29.8 billion in 2015, a 3.5% growth over the prior year and 2.9% annual growth rate since 2006. Industry revenues are expected to grow 2.6% annually to reach $33.9 billion by 2020. There are a variety of factors that impact growth of the substance abuse treatment market, including development of new treatments, drug availability and healthcare reform.

 

Industry Drivers

 

Increased exposure to drugs and alcohol–In the United States, illicit drug use and alcoholism have grown significantly among all age groups due to increased availability of prescription drugs and medication. This has resulted in an unfortunate trend of increased prescription medication abuse by secondary school and college-aged young adults.

 

Development of new treatments and programs

 

Clinical advancements in therapy and medication management have yielded new and better procedures for both psychological and detoxification treatments. Over the past several years, medication-assisted opioid therapy, which allows patients to rid their system of substance dependence through new-aged medication treatments, has led to an increased demand for treatment. Another driver is the future need for clinics to provide youth, elderly and gender-specific programs.

 

Healthcare reform and affordability

 

Healthcare in the U.S. has undergone significant changes in recent years that are favorable for the substance abuse treatment industry. Healthcare reform, specifically the Affordable Care Act (“ACA”), the Mental Health Parity and Addiction Equity Act (“MHPAEA”) and the Medicaid Certified Match Substance Abuse Program (“MCMSAP”), has led to more affordable substance abuse treatment.

 

Growth in private insurance

 

In the five years following the 2014 health insurance exchange implemented by healthcare reform, the number of people with private health insurance is predicted to significantly increase.

 

Increased Awareness

 

One of the biggest challenges for the industry has been the reluctance of substance abusers and addicts to undergo treatment. Individuals afflicted by substance abuse typically refuse treatment due to the social stigma associated with admitting they have a problem or lack of knowledge about the treatments available. However, recent efforts by health and government agencies have resulted in greater public awareness and acceptance of substance abuse as a disease.


Table of Contents

- 17 -



Autism Disorder and Treatment Industry

 

Although the specific causes of autism are still not known, one thing is. The rate is increasing, and the market for treatment is growing.

 

Based on new government data, 1 in 45 children in the United States, aged 3-17, have autism. This is up from only 1 in 150 children back in 2000.

 

Research firm, Market Data’s released new report entitled: “The U.S. Autism Treatment Market”, states that market data analysts estimate that there are 1.4 million American children with autism. Another 700,000 adults have autism, having “aged out” of children’s programs. And, 81% of autistic children are male.

 

The total annual costs for children with autism spectrum disorder (“ASD”) in the United States were estimated to be between $11.5 billion and $60.9 billion — a significant economic burden.

 

Insurance coverage is a problem, but the share of children with access to insurance coverage is expected to increase from the 36% level today. In addition, the number of self-funded private employers covering autism treatment continues to grow.

 

Autism Treatment Options

 

In the past, it was thought that the best way to treat the symptoms of autism was to medicate. Data suggest that approximately 58 percent of patients with a diagnosis of childhood autism receive some type of pharmaceutical treatment. However, this segment of the market has been shrinking in value as concerns continue over the side effects of commonly used drugs such as Risperdal.

 

Today, this attitude is changing, as Applied Behavior Analysis (“ABA”) programs have become more widespread and have displayed good outcomes. There are basically three types of ABA program providers: brick & mortar centers, community providers, and In-home therapists.

 

Many autism treatment organizations, and some of the largest competitors, are located in California. This is due to the fact that funding for treatment programs has been in place there since the 1990s, prior to the insurance mandates that were later put into place.

 

Market Opportunities

 

With healthcare costs continuously on the rise, the PBH Intrinsic Code is positioned to be unique as an evidenced based, and cost-effective approach in improving patient care.  The selection of the healthcare market as the focal effort of Parallax is a choice based upon the market size and market demand for outcomes improvement across the market that is both target rich and highly scalable.

 

An estimated one in four adults (about 60 million Americans) experiences mental illness in a given year. 

About 14 million people live with a serious mental illness. 

Approximately 20 percent of youth ages 13 to 18 experience severe mental disorders in a given year. 

7 percent of American adults live with major depression. 

An estimated 18 percent of American adults live with anxiety disorders (e.g., panic disorder, OCD, PTSD). 

About 9 million adults have co-occurring mental health and addiction disorders. 

20 million Americans suffer from substance abuse. 

 

In addition, there is a critical mental health provider shortage creating significant access to care issues:

 

Only 40 percent of Americans with mental illness report receiving treatment. 

One mental health provider exists for every 790 individuals. 

Approximately 4,000 Mental Health HPSA (professional shortage areas) exist which is based on a psychiatrist to population ratio of 1:30,000 -- meaning it would take approximately 3,000 additional psychiatrists to eliminate the current mental health HPSA designations. 

A report to Congress found that 55 percent of the nation's 3,100 counties have no practicing psychiatrists, psychologists or social workers. 

 

There exists an abundance of opportunities for PBH that are focused on the use of the Company’s patented Intrinsic Code technology. The market opportunities currently being pursued for the Intrinsic Code include, but are not limited by:

 

Integration within PHM’s remote patient care platform for goal obtainment and mastery within healthcare operations 

Integration within PHM’s Compass mobile smartphone applications targeted at and focused on specific user applications including but not limited to remote patient care, doctor decision support, patient empowerment, population health, ASD (Autism), chronic disease management and hospital readmissions reduction.  

Development alongside the SPARKS Reader, the PDI patented handheld featuring immunoassay blood testing and FDA approved tests, to  enable a complete suite of platform-based offerings for medical practitioners including individual doctor’s offices, doctor groups, accredited nursing, and hospital operations.  

 

Management is seeking additional opportunities with or in the study of the following markets:

 

Environmental 

Economic 

Healthcare  

Enterprise licensing 

E-learning applications 

Professional sports 

Fitness  

 

Management is also in the process of identifying the comprehensive patent landscape, and determining the best course and greatest value accretion in the prospective markets that will be approached through the patent and intellectual property licensing,  including the market values related to patent infringement and outbound licensing opportunities centered around its Intrinsic Code as well as the adjacent assets held by Parallax’s subsidiaries.

 

Autism Market

 

The U.S. autism treatment market was estimated to be valued at $1.85 billion as of 2016, growing to $1.87 billion last year. Market data forecasts 3.9% average yearly growth, to $2.23 billion by 2022. This could be conservative, as insurance coverage is improving. In addition, venture capital firms are starting to take notice of investment opportunities in this market.

 

The “average” ABA center grosses about $821,000, and many are non-profit organizations. Many programs now have waiting lists and there is a shortage of qualified supervisors.

 

Nine large multi-site ABA program providers operate an estimated 296 brick & mortar centers and employ thousands of therapists. Together, they account for about $390 million in revenues — a 38% market share of ABA programs.

 

Revenues of ABA (applied behavioral analysis) programs are estimated to generate $1.07 billion in revenues this year, outpacing sales of prescription drugs used for autism symptoms.


- 18 -



Competitive Landscape

 

PBH competes with other technology consulting companies and provides Parallax with key technological advantages over the competing companies in the remote patient care and within the diagnostics. Within licensing, PHM competes with other value-based contracting companies and technology companies like Oracle, Accenture and IBM, that have taken the same systems integration go-to-market approach.

 

Intellectual Property (Behavioral Health)

 

The Company, through a n Intellectual Property Purchase Agreement with ProEventa, Inc., acquired all rights, title and interest in and to the patent entitled “Platform for Data Driven Outcomes.” The patent has been granted in the U.S. under patent #10,061,812, and applications have been filed worldwide. It has been published in the UK under filing GB2526749. A third filing is pending issuance in Australia. Along with the patents, PBH acquired the technology platform referred to as Reliable Evidenced Based Outcomes Optimization Technologies, (”REBOOT”), a technology platform specifically designed to improve health treatment outcomes using proprietary applied behavioral analytics technology systems. PBH rebranded the technology in 2018, and the proprietary software is now known as the Intrinsic Code (“Intrinsic Code”).

 

For more information on these patent applications, please see “INTELLECTUAL PROPERTY SUMMARY” section below.  

 

Government Regulations

 

Mental health and substance abuse services are subject to many federal, state and local regulations regarding licensing, operations, facility ownership, reimbursement rates and procedures. These regulations and strict licensure requirements create high barriers to entry for the industry. Licensing prerequisites typically relate to the provider’s medical qualifications, personnel and equipment, staff-to-patient ratio, adequate records maintenance, rate-setting and compliance with standard building and safety codes. Expansion of substance abuse facilities are also subject to state regulations. The construction of new facilities; expansion of existing facilities; transfer or change of ownership; and the addition of new beds, services or equipment may be subject to state laws that require prior approval by regulatory agencies under certificate of need (“CON”) laws. CON laws generally require that a state agency determine the public need for construction or acquisition of facilities/addition of new services.

 

The Government regulations also having a unique impact on Parallax are the HIPPA, Healthcare Information Privacy Protection Act, which impact our management and controls around the data we collect and encounter throughout the PBH operations.  Also, the medical payments and reimbursements of the State and local governments know as Medicare and Medicaid require consistent and diligent management both in following the advantageous changes in the move towards connected care and greater reimbursements and also regulations and requirements with each approved connected care treatment.  Lastly, there is additional regulation of the medical practice from American Medical Association which all our US clients have requirements and regulations that affect how our PBH business is operated to both be in compliance and in alignment with our customers whom require unique reporting and other data and service related processes due to the regulation from these organizations and others. 

 

Principal Suppliers

 

As of December 31, 2017, the principal suppliers for the Behavioral Health platform were:

 

Amazon Web Services, Seattle, WA 

HIPAA-compliant secure server environments for hosting and management of GHOP, Intrinsic Code and Compass.

La Frontera’s Empact Suicide Prevention Center, Tempe, AZ 

Largest CARF certified behavioral health suicide prevention call center in United States.

 

The Company relies upon these suppliers to provide the majority of its delivery of its remote patient monitoring systems and services.  The services are web based and although the Company relies on these vendors, it can also hold them accountable, receive volume-based pricing, discounts and partnership advantages through the competition of its suppliers. Parallax has the ability to change vendors at any time in all service and product lines. Further, PBH is working towards the elimination of its reliance on software and hardware providers related to its in-home behavioral health offerings and services.


Table of Contents

- 19 -



INTELLECTUAL PROPERTY SUMMARY

 

The Company retained the services of the Intellectual Property Network (“IPN”) to provide Intellectual Property protection recommendations for all of the Company's Intellectual Property, open patent applications and products, both domestically and internationally.  IPN informs the Company and its shareholders of the accurate and current state of the commercial patent pending coverage, and where possible to identify the existence of novel and patentable inventions present in the current innovation initiative.  IPN concluded that the Company has a strong patent portfolio protecting its business and recommended that the Company aggressively proceed with additional patent applications to protect the Company’s inventions and innovations.  

 

Patents, Patent Applications, Exclusive Licenses and Patent Portfolio Overview

 

I.The Company, through a License Agreements with Montecito BioSciences, Ltd., acquired the worldwide exclusive rights to sub-license, sell, have sold, make have made, develop, have develop, further develop and modify, or to have further developed or modified, within the field of use set forth in the agreement, the following patents and/or patents pending: 

 

1. Patent 8,920,725 and 9,170,258 - “Portable Apparatus for Improved Sample Analysis” 

 

The present invention is an improved apparatus for sample analysis. The apparatus employs an assay component containing a membrane having one or a plurality of analyte-specific binding agents attached thereto, a means for absorbing liquid, and a piston means for drawing analytes through said membrane into said means for absorbing liquid. The apparatus is configured to be portable and provide a detector for detecting binding of an analyte to an analyte-specific binding agent, a plurality of data acquisition components, and a computer for integrating, analyzing and storing the detected analyte specific binding and acquired data.

 

This Patent and pending application(s) cover the Company’s SPARKS Mobile hand-held analyzer, which is used in conjunction with the Target System Test Cartridge. The hand-held Target Analyzer™ device is capable of housing and analyzing two assay cassettes, and optionally features wired or wireless data transfer and multiple data acquisition components including a keypad, a touch-pad, a barcode wand and / or a finger print reader.  On August 23, 2013, the Company was notified that its Chinese Patent Application No. 200780039901.X “Portable Apparatus for Improved Sample Analysis” had been granted by the States Intellectual Property Office of the Peoples Republic of China. Patents were also issued in Hong Kong and Macao.  The Company filed in India under a New Indian Patent Application based on the PCT Application No. PCT/US2007/082499 The case is currently pending.

 

Following is the family of cases under Patent 8,920,725 and 9,170,258:

 

ApplicationCountryDate FiledStatusDate GrantedPatent Number 

1.60/863,241United States10/27/2006ProvisionalN/AN/A - continued under 1a 

1a.11/924,033United States10/25/2007AbandonedN/AN/A - continued under 1b 

1b.13/248,307United States09/29/2011Granted12/30/20148,920,725 B2 

1c.14/553,011United States11/25/2014Granted10/27/20159,170,258 B2 

1d.CN101558302China10/25/2007Granted08/23/2013CN200780039901.X 

1e.HK2010010103654Hong Kong10/25/2007Granted03/28/2014HK1137813 

1f.MO J/001298Macau10/25/2007PendingPendingPending 

1g.IN785/MUMNP/2009India10/25/2007PendingPendingPending 

 

[1] Patent Application US11/924,033 is being prosecuted worldwide.  The now abandoned EPO Application No. 07854420.2 was filed in the following designee countries; Austria, Belgium, Bulgaria, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Iceland, Ireland, Italy, Latvia, Lithuania, Luxembourg, Monaco, Netherlands, Poland, Portugal, Romania, Slovakia, Slovenia, Spain, Sweden, Switzerland, Liechtenstein, Turkey and the United Kingdom.  

 

2. Application 14/492,641 - “Method for Determining the Immune Status of a Subject” 

 

The present invention is a method for using levels of soluble Clusters of Differentiation (CD) proteins, or cell surface-localized CD proteins extracted from T lymphocytes for determining the immune status of a subject. The present invention also a kit containing a CD protein extraction means and at least one antibody which specifically binds a CD protein for use in carrying out the method of the invention. This family of cases covers a technique and kit for assessing immune status, e.g., in HIV patients, based upon the amount of soluble or surface-localized CD3-CD4, and / or CD8 protein present in a patient sample. This method and kit is an alternative to conventional cell sorting technologies.

 

ApplicationCountryDate FiledStatusDate GrantedPatent Number 

2.60/845,395United States09/18/2006ProvisionalN/AN/A - continued under 2a 

2a.11/856,925United States09/18/2007AbandonedN/AN/A - continued under 2b 

2b14/492,641United States09/22/2014PendingPendingPending 

 

3. Application 12/769,036 - “Method of Identifying Drugs, Targeting Moieties or Diagnostics” 

 

The present invention relates to a method for identifying a binding agent or epitope for use in drug design, drug targeting or diagnostics. The method employs contacting and sorting binding agents and cognate epitopes from collections thereof, characterizing the binding agent and cognate epitope, detecting the level or location of the epitope in a sample using the binding agent, and correlating the level or location of the epitope in the sample with the presence or stage of a disease or condition to identify novel drugs, targeting moieties, or diagnostic agents. This family of cases covers a technique for obtaining a population of antibodies that specifically binds to a corresponding population of antigens, without any a priori information about either population. The antigens identified by the method are subsequently characterized and correlated with the presence or stage of a disease or condition there by serving as a target for drug design, drug targeting or diagnostics.

 

ApplicationCountryDate FiledStatusDate GrantedPatent Number 

3.60/608,342United States09/09/2004ProvisionalN/AN/A - continued under 3a 

3a.11/221,038United States09/07/2005AbandonedN/AN/A - continued under 3b 

3b12/769,036United States04/28/2010PendingPendingPending 

 

4. Patent 9,573,990 - “Method of Producing a Plurality of Isolated Antibodies to a Plurality of Cognate Antigens” 

 

The present invention relates to a method for producing high affinity antibodies that are antigen-specific. The method involves binding a plurality of antibody-producing B-cells from a mammal to a plurality of cognate antigens; sorting the bound antibody-producing B-cell and cognate antigen; amplifying nucleic acid sequences encoding each antibody, or fragment thereof, from the B-cells; and expressing each antibody in a protein expression system. Antibodies produced in this manner are useful in diagnostic and therapeutic applications. This family of cases covers a technique for obtaining a population of antibodies produced by B-cells, without any a priori information about the population of antibodies, and use of the same in an array for profiling antigen expression.

 

ApplicationCountryDate FiledStatusDate GrantedPatent Number 

4.60/608,526United States09/09/2004ProvisionalN/AN/A - continued under 4a 

4a.11/221,252United States09/07/2005AbandonedN/AN/A - continued under 4b 

4b13/253,366United States10/05/2011Granted02/21/20179,573,990 

 

5. Application 14/786,282 - "Flow Through Testing System with Pressure Indicator" 

 

This family of cases covers an improved assay cassette with pressure-sensitive microcapsules for ensuring that a sufficient reduction in pressure is achieved there by maximizing contact between the sample and analytic compound. A device for performing immunoassays on analytes. The device includes an immunosorbent membrane, an absorbent material, a piston component located below said absorbent material to draw analytes in a sample through the immunosorbent membrane into the absorbent material, and discrete groups of pressure-sensitive microcapsules located on the immunosorbent membrane.

 

ApplicationCountryDate FiledStatusDate GrantedPatent Number 

5.61/814,916United States04/23/2013ProvisionalN/AN/A - continued under 5a 

5a.14/786,272United States04/23/2014PendingPendingPending 

5b.PCT14/35073United States10/22/2015PendingPendingPending 

 

Summary of Open Applications available for continuation filings (from above):

 

2b. US14/492,641 - “Method for Determining the Immune Status of a Subject” 

3b. US12/769,036 - “Method of Identifying Drugs, Targeting Moieties or Diagnostics” 

5a. US14/786,272 - "Flow Through Testing System with Pressure Indicator" 

 

For further information on the exclusive license of the Patents and Patent Applications above, and the complete text of the License Agreement and subsequent Modification, please refer to Exhibits 10.20 and 10.22, respectively, to the Company’s Current Report filed November 15, 2012 on Form 8-K.

 

II.The Company, through an Assignment Agreements with La Frontera Community Solutions, Inc., acquired all worldwide rights, title and interest in and to the following patent applications and the invention in its entirety: 

 

1.Application 14/979,889 – “Remote User Monitoring System”  

 

A system and method for monitoring a status of a user. One or more biometrics associated with a user in a residence where the user resides are sensed. A status of the user is determined in response to sensing the one or more biometrics. One or more questions about the status to the user are communicated. One or more answers to the one or more questions communicated to the user are received. The status is communicated to an administrator of the residence. The status is communicated in response to one or more of the answers.

 

ApplicationCountryDate FiledStatusDate GrantedPatent Number 

1.14/979,889United States12/28/2015PendingPendingPending 

 

2.Application 14/979,742 – “Remote Medication Delivery Systems” 

 

A system and method for medication delivery. Information is received indicating a user is scheduled to receive medication. A route between a dispensary storing the medication and a location of the user is determined. The medication is sent in a container from the dispensary to the location utilizing the route.

 

ApplicationCountryDate FiledStatusDate GrantedPatent Number 

2.14/979,742United States06/29/2017PendingPendingPending 

 

For further information on the exclusive license of the Patent Applications above, and the complete text of the Intellectual Property Purchase Agreement, please refer to Exhibit 10.33 to the Company’s Current Report filed September 26, 2016 on Form 8-K.

 

III.The Company, through a License Agreements with ProEventa, Inc., acquired all rights, title and interest in and to the following patent applications and the invention in its entirety.  The US patent was granted to Parallax Behavioral Health, Inc. on August 28, 2018: 

 

1.Patent 10,061,812 – “Platform for Optimizing Data Driven Outcomes “ 

 

A system, method, server and computer readable medium for tracking outcome specific data. Input establishing accounts for providers serving clients is received. The accounts are stored in a server. Each of the clients is assigned to one or more of the providers in response to selections from an administrator. Data associated with each of the clients received from the providers is compiled utilizing computing or communications devices in communication with the server. The compiled data is presented visually in response to a user request. The process allows for optimization of best practices, successful actions, and success-based plan execution, which is identified through automatic data-mining and analysis as well as user specified parameters, algorithms, and analytics.  The process can be utilized by a client, patient, student, service provider, program, product, service, device, organization, business, department, or so forth.  The tool can be utilized across various industries for client behavior management, educational instruction, school improvement activities, program evaluation, organizational key performance indicators, financial management, weight management, tracking insurance claims, or so forth.

 

This patent covers the intellectual property formerly known as REBOOT, an acronym for “Reliable Evidence Based Outcomes Optimization Technologies”, which was rebranded in 2018 as the “Intrinsic Code,” a structured, scalable and sustainable software system used to identify, monitor, and evaluate a single user or an entire organization's progress towards mastery of any achievable task, objective or goal.

 

ApplicationCountryDate FiledStatusDate GrantedPatent Number 

1.61/791,218United States03/15/2013ProvisionalN/AN/A - continued under 1a 

1a.14/212,429United States03/14/2014Granted08/28/201810,061,812  

1b.GB1517371.9United Kingdom03/14/2014Published12/02/2015Publication GB2526749 

1c.2014/144749A1Worldwide09/18/2014Pending 

 

 

For further information on the exclusive license of the Patent Application above, and the complete text of the Intellectual Property Purchase Agreement, please refer to Exhibit 10.33 to the Company’s Current Report filed May 4, 2017 on Form 8-K.

 

There can be no assurance that the Company will be granted patents for any of the patent applications it has filed with the USPTO or other patent organization worldwide.

 

Expired Patents

 

The Target System and certain of its related components were previously issued patents by the USPTO.  The following previously-issued patents have expired:  

 

USPTO Patent #

Description

Date Filed in US

Date Expired

US4,748,042

Target Ringing & Spotting Machine (method and Apparatus for Imprinting membrane with pattern of antibody)

May 31, 1988

May 31, 2008

US4,797,260

Target Cassette (Antibody testing system)

January 10, 1989

January 1, 2009

US5,137,691

Target Cassette with Removable Air Gap (Antibody testing system with removable air gap)

August 11, 1992

August 11, 2012

 

Trademarks

 

The Company will also utilize trademark applications to protect its Intellectual Property that may not be suitable for patent protection. Unlike patent applications, which in many cases must be filed in advance of a particular date, there is no specific date by which a trademark application must be filed. Instead, the time constraint is in a different direction. In the United States, an ordinary so-called "use" trademark application can only be filed after the goods or services have been in interstate commerce.

 

On January 2, 2016, trademark application 86/863,854 was filed with the USPTO for the word mark, “QOLPOM”.  On September 5, 2017, the trademark was registered, registration number 5279137.


Table of Contents

- 20 -



Facilities

 

The Company’s principal executive office is located at 1327 Ocean Avenue, Suite B, Santa Monica, California, 90401, with operations during 2017 at 465 N. Roxbury Drive, Beverly Hills, CA 90210. The Company’s Beverly Hills location was closed in December 2017. The Company’s telephone number is (310) 899-4442 (Santa Monica).

 

For additional information on the leased properties in Beverly Hills, CA, see “ITEM 2.  PROPERTIES” section contained within this annual report.

 

Employees

 

As of December 31, 2017, the Company had 8 employees, exclusive of its directors and executive officers.

 

The Company currently has 8 employees, exclusive of its directors and executive officers.

 

Research and Development

 

The Company has incurred no expenditures relating to the research and development of its proprietary medical diagnostic equipment during 2017 and 2016, including costs for consultants, costs to develop and manufacture prototype units and assays, costs to conduct clinical trials, and costs incurred to develop new products.  

 

Reports to Security Holders

 

The Company is not required to deliver an annual report to its stockholders, but will voluntarily send an annual report, together with the Company’s annual audited financial statements upon request. The Company is required to file annual, quarterly and current reports, proxy statements, and other information with the Securities and Exchange Commission. The Company’s Securities and Exchange Commission filings are available to the public over the Internet at the SEC's website at www.sec.gov.

 

The public may read and copy any materials filed by the Company with the SEC at the SEC's Public Reference Room at 100 F Street, NE, Washington DC 20549. The public may obtain information on the operation of the Public Reference Room by calling the SEC at 1-800-SEC-0330. The Company is an electronic filer. The SEC maintains an Internet site that contains reports, proxy and information statements, and other information regarding issuers that file electronically with the SEC. The Internet address of the site is www.sec.gov.

 

ITEM 1A. RISK FACTORS 

 

The Company is a smaller reporting company as defined by Rule 12b-2 of the Securities Exchange Act of 1934 and is not required to provide the information under this item.

 

ITEM 1B. UNRESOLVED STAFF COMMENTS 

 

None.

 

ITEM 2. PROPERTIES 

 

The Company’s principal executive offices are located at 1327 Ocean Avenue, Suite B, Santa Monica, CA 90401.  Its pharmacy operations located at 465 N. Roxbury Drive, Beverly Hills, CA 90210 ceased operations in December 2017, and the space was vacated in January 2018.  As of December 31, 2017, the Company sub-leases the Santa Monica space for approximately $5,600 a month.  This space is sufficient to meet the Company’s needs at December 31, 2017.  However, once the Company expands its business to a significant degree, it will require additional space. The Company does not currently own any real estate.

 

Dispute with Landlord-Beverly Hills, CA

 

Upon the completion of the acquisition of RoxSan Pharmacy, Inc. in August 2015, the Company became aware that the former owner, Shahla Melamed (“Melamed”), among other things, failed to properly notify the landlord or the Roxbury Drive property owners (the “Lessors”) of the change in ownership of the pharmacy, as required in the lease agreements.  Subsequently, in an effort to unwind the Company’s acquisition of the pharmacy, Melamed has attempted to undermine the Company’s efforts to obtain any lease assignment or new lease from the Lessors.  As a result, no lease assignments or lease agreements were made as of December 31, 2017, and the Company vacated the space in January 2018.

 

ITEM 3. LEGAL PROCEEDINGS 

 

From time to time, the Company may be involved in litigation relating to claims arising out of its operations in the normal course of business.  The Company knows of no material, existing or pending legal proceedings against it, nor is the Company involved as a plaintiff in any material proceeding or pending litigation, beyond those defined below.  There are no proceedings in which any of its directors, officers or affiliates, or any registered or beneficial shareholder, is an adverse party or has a material interest that is adverse to the Company’s interests.

 

Dispute with Former Owner of RoxSan

 

In October 2015, shortly following the Company's acquisition of RoxSan, Shahla Melamed (“Melamed”), initiated two (2) legal actions against the Company in the Superior Court of the State of California, County of Los Angeles, West District, Shahla Melamed v. Parallax Health Sciences, Inc., action numbers SC 124873 and SC 125702.  

 

In the matter, action No. SC 124873, Melamed sought rescission of the August 13, 2015 Purchase Agreement. During the proceedings, Melamed also contended that the Company owed Melamed monies for, among other things, expenses paid by Melamed on behalf of the Company.  As a result, the Court split the action into two separate rulings: (1) Rescission Phase and (2) Accounting Phase.

 

Action No. SC 124873-Rescission Phase: 

 

In the Matter, action no. SC 124873, rescission was sought by Melamed on the basis that, allegedly, in order to acquire the Pharmacy, the Company and its principals had allegedly defrauded Melamed, there had allegedly been a complete failure of consideration, and a unilateral mistake was allegedly made on the part of Melamed.  Subsequently filed pleadings by the Company and RoxSan in action no. SC 124873 allege, among other things, that Melamed misrepresented the true earnings and source of income for the pharmacy business and had engaged in a fraudulent and illegal scheme to ship medications to states where her pharmacy was not licensed prior to the sale of the Pharmacy.

 

Final Ruling:  On March 17, 2017, the Court ruled in favor of the Company, and issued that Melamed is not entitled to rescission of the Purchase Agreement.  The ruling of the Court stated that no fraud on the part of the Company or its principals had been demonstrated.  The Court further ruled that there had been no failure of consideration, and that Melamed’s entry into the Agreement was not a result of a unilateral mistake on the part of Melamed.  The Minutes of the Ruling were entered by the County Clerk on March 17, 2017.


Table of Contents

- 21 -



Action No. SC 124873-Accounting Phase: 

 

In the Matter, action No. SC 124873, Melamed contended that the Company owed Melamed monies for, among other things, expenses paid by Melamed post-Closing.  An accounting was presented by Melamed’s expert, BDO Seidman (“BDO”), alleging that the Company owed Melamed in excess of $500,000.  The Company disputed this vigorously and prepared a 400+ page analysis (the “Analysis Report”) of the BDO reconciliation report.  The Analysis Report identified errors in the BDO report in excess of $900,000 and found that Melamed owed the Company over $400,000.  Melamed argued the findings in the Analysis Report. Consequently, due to the complexities of the accountings, the Court ordered a third-party adjudicator with an accounting background to review both the BDO report and the Company’s Analysis Report.

 

Draft Ruling: On July 24, 2017, in the Matter, action No. SC124873, the Company was notified that the results of the reconciliation review performed by third-party adjudicator were in favor of the Company in the amount of $412,948.  Melamed objected to the adjudicator’s findings, and a final hearing was held in January 2018.  A final judgment is pending for the Court’s decision on the exact monies owed by Melamed to the Company.

 

Action No. SC125702: 

 

In the Matter, action No. SC125702, Melamed alleges that the Company is in default under the terms of the Purchase Agreement and Secured Note, and the Company’s termination of Melamed’s employment agreement.  The Company firmly believes that it had adequate grounds to justify the termination of the employment, that it acted within its rights, and shall prevail in these proceedings.  A trial date is currently set for July 2018.

 

Action No. SC 124898:  

 

The Company has initiated legal action against Melamed and filed a complaint, action number SC 124898, in the Superior Court of the State of California, County of Los Angeles, West District, Parallax Health Sciences, Inc., et al. v. Shahla Melamed, et al.  The Complaint in that action alleges that Melamed has breached several obligations under the Purchase Agreement, and the Company is seeking to reduce the Secured Note due to undisclosed material changes in the business. A trial date is currently set for July 2018.

 

As part of the Company’s pleadings to the courts, the Company has presented the following matters:

 

Purchase Price Dispute 

 

Included in the Acquisition Agreement for RoxSan Pharmacy, Inc., and as part of the negotiated purchase price, were representations and warranties made by the former owner involving certain primary revenue streams and related contracts.  Shortly after the closing, however, management discovered that these representations were substantially inaccurate and/or completely false.  These inaccuracies, and the improper disclosures and/or omissions made by the former owner during negotiations, would have significantly affected the purchase price and related note payable.  As a result, among other things, management has initiated legal action against the former owner to seek a reduction in the purchase price.  

 

Included in the false representations made by the former owner were prescription revenues in excess of $8 million (and $16 million prior to the change in ownership) related to workers compensation claims that the former owner warranted as collectible.  The insurance claims related to these prescriptions, which originated from and were provided to the pharmacy by the former owner's direct family members, were investigated by a third-party expert retained by the Company, and the claims were substantially identified as fraudulent.  The former owner's family member has been indicted by the Department of Justice for among other things, insurance fraud.

 

In addition, management engaged a third-party to perform a valuation of the Pharmacy, utilizing revised inputs that more accurately reflected the Pharmacy's revenue streams as of the date of Acquisition.  The valuation performed resulted in a fair market value of $4.7 to $5.2 million. After careful consideration, and based upon these significant differences, management has determined that the purchase price and related promissory note of $20.5 million does not fairly represent the fair market value at the date of purchase.  The Company has, therefore, applied a discount to the note of $15.3 million, to reduce the purchase price and related note to its estimated fair market value of $5.2 million, utilizing the higher value on the range as a conservative measure.  

 

The valuation performed does not include the effects of any liabilities the former owner omitted or damages caused to the Company as a result of the former owner and her immediate family members connected to the Pharmacy.

 

Control of Funds Dispute / US Postal Interference 

 

For a period of time immediately after the closing of the Acquisition, the Melamed would not relinquish control of the Pharmacy's bank accounts, and collected the Pharmacy's incoming cash revenues, refusing to transfer the funds to the new ownership. Furthermore, when the Company attempted to change the corporate records and signatories on the existing bank accounts, the former owner disputed the changes, resulting in approximately $180,000 in corporate funds being frozen and held for adjudication. During this period, the Company was forced to request that the former owner pay the Pharmacy's operating expenses.  At no time after the Company opened new accounts did the former owner cooperate with the transference or willingly relinquish control of the Pharmacy's operating cash flow or incoming cash revenues.

 

The former owner continued to interfere in the transference of control of the Pharmacy by submitting change of address forms to the US Postal Service, wherein the former owner diverted the Pharmacy mail to her home address.  Once this was discovered and rectified with the post office, the former owner filed another change of address to divert mail to a post office box.  During these periods of time, the former owner received check payments and negotiated the checks by opening up a bank account utilizing a DBA, "Roxsan Pharmacy."  The Company was able to identify some of the checks the former owner negotiated by directly contacting the payer and receiving copies of the cancelled checks, with the former owner's signature endorsement and account number on the check.

 

On May 14, 2018, pursuant to a unanimous resolution of the Boards of Directors of RoxSan Pharmacy, Inc. and Parallax Health Sciences, Inc., RoxSan filed a Chapter 7 petition in the United States Bankruptcy Court for the Central District of California.  Mr. Timothy Yoo was appointed trustee on May 15, 2018.  In connection with this filing, RoxSan seeks to discharge approximately $5 million of liabilities owed to various parties including more than $1 million owed to the Company.


- 22 -



Disputes with Former Executives

 

Action No. CV2017-052804 

 

On March 9, 2017, Mr. Dave Engert filed a lawsuit in Arizona and then later changed the venue to Federal Court in Southern California claiming, among other issues, that monies are owed to him under his Consulting Agreement and that his termination was without cause.  The Company is in disagreement with the position and claims made by Mr. Engert, and as such has counter claimed against Mr. Engert asserting that the Company intends to vigorously defend its position.

 

On October 23, 2017, the Company filed a response and counterclaims against Mr. Engert for an amount exceeding $100,000.  The counterclaims include possible fraud and negligence committed by Mr. Engert and Mr. J. Michael Redmond, former successor Chairman of Mr. Engert, director, President and Chief Executive Officer of the Company and former President, Chief Executive Officer, Chairman and director of RoxSan Pharmacy, Inc.

 

Action No. BC700070 

 

On March 28, 2018, Mr. J. Michael Redmond filed a lawsuit against the Company and RoxSan Pharmacy, Inc. in the United States District Court, Central District of California for an amount exceeding $75,000.  The Company intends to vigorously defend against this action. There are counterclaims that include possible fraud and negligence committed by Mr. Redmond, former successor Chairman of Mr. Engert, director, President and Chief Executive Officer of the Company and former President, Chief Executive Officer, Chairman and director of RoxSan Pharmacy, Inc.

 

Disputes with Creditors/Vendors

 

Action No. SC127712 

 

On or about June 20, 2017, American Express Bank, FSB filed suit against RoxSan Pharmacy, Inc. in Superior Court of California, County of Los Angeles for an amount of $996,622 in connection with RoxSan’s merchant financing loan.  On or about June 27, 2017, American Express Travel Related Services Company, Inc. filed suit against RoxSan Pharmacy, Inc. in Supreme Court of New York, County of New York in the amounts of $153,500 and $273,500 in connection with RoxSan’s credit card obligations.  On July 31, 2017, and August 16, 2017, the Company entered into stipulation and settlement agreements for these matters to make payments in lieu of further litigation at this time.

 

All five (5) legal matters are currently pending.

 

 

ITEM 4.MINE SAFETY STANDARDS  

 

Not applicable.


Table of Contents

- 23 -



PART II

 

ITEM 5.MARKET FOR COMMON EQUITY AND RELATED STOCKHOLDER MATTERS  

 

The Company’s Common Stock is quoted on the OTC Quotation Board “OTCQB – U.S. Registered” under the trading symbol PRLX.QB. The following table sets forth the high and low bid prices for its Common Stock per quarter as reported by the OTCQB for the last two years. These prices represent quotations between dealers without adjustment for retail mark-up, markdown or commission and may not represent actual transactions.

 

The high and low prices of the Company’s common shares for the periods indicated below are as follows:

 

Quarter Ended

High

Low

December 31, 2017

$0.11

$0.10

September 30, 2017

$0.24

$0.22

June 30, 2017

$0.21

$0.21

March 31, 2017

$0.24

$0.20

December 31, 2016

$0.14

$0.14

September 30, 2016

$0.10

$0.07

June 30, 2016

$0.03

$0.03

March 31, 2016

$0.05

$0.04

 

The Company’s common stock is subject to rules adopted by the Commission regulating broker dealer practices in connection with transactions in “penny stocks.” Those disclosure rules applicable to “penny stocks” require a broker dealer, prior to a transaction in a “penny stock” not otherwise exempt from the rules, to deliver a standardized list disclosure document prepared by the Securities and Exchange Commission. That disclosure document advises an investor that investment in “penny stocks” can be very risky and that the investor’s salesperson or broker is not an impartial advisor but rather paid to sell the shares. The disclosure contains further warnings for the investor to exercise caution in connection with an investment in “penny stocks,” to independently investigate the security, as well as the salesperson with whom the investor is working and to understand the risky nature of an investment in this security. The broker dealer must also provide the customer with certain other information and must make a special written determination that the “penny stock” is a suitable investment for the purchaser and receive the purchaser’s written agreement to the transaction. Further, the rules require that, following the proposed transaction, the broker provide the customer with monthly account statements containing market information about the prices of the securities.

 

Record Holders

 

The Company’s common shares are issued in registered form. Action Stock Transfer Corp., 2469 E. Fort Union Blvd., Suite 214, Salt Lake City, UT 84121 (Telephone 801-274-1088, Facsimile 801-274-1099) is the registrar and transfer agent for the Company’s common shares.

 

As of December 31, 2017, pursuant to Action Stock Transfer Corp., the shareholders' list of the Company’s common shares showed 73 registered shareholders and 117,754,530 shares outstanding. The total outstanding shares does not include 19,000,000 shares to be issued, of which 3,950,000 in common stock purchases, 2,100,000 in connection with debt settlements, and 7,375,000 in connection with services provided to the Company, were issued in April 2018; and 5,575,000 which are unvested at December 31, 2017.

 

As of December 31, 2017, an aggregate of 863,691 shares of the Company’s preferred stock were issued and outstanding and are held by 5 shareholders. All 823,691 Series A and 40,000 Series B preferred shares are convertible into the Company’s common stock at a conversion ratio of 20 shares of common stock for each preferred share held. Series A and Series B preferred shares include 100% and 50% warrant coverage, respectively (see Warrants).

 

Dividends

 

The Company has not declared any dividends on its common stock since the Company’s inception. There is no restriction in the Company’s Articles of Incorporation and Bylaws that will limit its ability to pay dividends on its common stock. However, the Company does not anticipate declaring and paying dividends to its shareholders in the near future. 

 

Dividends are payable semi-annually on the Company’s Series A preferred stock at a rate of 7% per annum, and 10% per annum on Series B preferred stock.  Dividends may be paid in kind, at the option of the Company, to the extent that if the Company is not legally permitted to distribute cash dividends, it shall pay dividends in the form of preferred shares equal to the amount of the dividend. No dividends have been declared on the Company’s preferred stock.

 

Equity Compensation Plan Information

 

In 2015, the Company adopted and approved the 2015 Incentive Compensation Plan ("the 2015 Plan"), wherein ten million (10,000,000) restricted shares of common stock were reserved for issuance. The 2015 Plan was intended to assist the Company in securing and retaining key employees, directors and consultants by allowing them to participate in the Company's ownership and growth through the grant of incentive and non-qualified options. The 2015 Plan is currently administered by the Company's Board. Subject to the provisions of the plan, the board will determine who shall receive options, the number of shares of common stock that may be purchased under the options.

 

In 2016, the Company adopted and approved the 2016 Incentive Compensation Plan ("the 2016 Plan"), wherein ten million (10,000,000) restricted shares of common stock were reserved for issuance. The 2016 Plan was intended to assist the Company in securing and retaining key employees, directors and consultants by allowing them to participate in the Company's ownership and growth through the grant of incentive and non-qualified options. The 2016 Plan is currently administered by the Company's board of directors. Subject to the provisions of the plan, the board will determine who shall receive options, the number of shares of common stock that may be purchased under the options.

 

As of December 31, 2017, the Company has granted options to purchase an aggregate of 20,975,000 shares, net of expirations and forfeitures. In connection with the options granted, a total of $1,679,765 has been recorded as deferred stock option compensation during the year ended December 31, 2017, of which $493,291 was expensed in prior years, $589,679 was expensed in 2017, and $1,319,010 will be expensed over the next 33 months.


- 24 -



Warrants

 

In connection with 823,691 shares of Series A preferred stock issued and outstanding as of December 31, 2017, the 15,262,491 underlying warrants have expired.

 

In connection with 40,000 shares of Series B preferred stock issued and outstanding as of December 31, 2017, the Company issued warrants to purchase 400,000 shares of common stock at an exercise price of $0.75 per share for a period of two (2) years.

 

In connection with certain convertible promissory notes issued in 2017, the Company issued warrants to purchase 3,905,000 shares of common stock at an exercise price of $0.25 per share for a period of three (3) years.

 

In connection with a certain debt settlement in 2017, the Company issued warrants to purchase 100,000 shares of common stock at an exercise price of $0.21 per share for a period of three (3) years.

 

In connection with a certain inventory security agreement issued in 2017, the Company issued warrants to purchase 800,000 shares of common stock at an exercise price of $0.10 for a period of three (3) years.

 

In connection with certain consulting agreements entered into in 2017, the Company issued warrants to purchase 1,000,000 shares of common stock.  The warrants are exercisable for a period of five (5) years at the following exercise price: 250,000 at $0.15 per share, 250,000 at $0.25 per share, 250,000 at $0.35 per share, and 250,000 at $0.60 per share.

 

In connection with certain consulting agreements entered into in 2017, the Company issued warrants to purchase 1,000,000 shares of common stock at an exercise price of $0.15 per share for a period of three (3) years.

 

As of December 31, 2017, the Company had 7,205,000 warrants issued and outstanding.  The number of shares of common stock underlying the warrants and the exercise price are subject to adjustment upon certain events.

 

Purchase of Equity Securities by the Issuer and Affiliated Purchasers

 

The Company did not purchase any shares of its common stock or other securities during the year ended December 31, 2017.

 

Recent Sales of Unregistered Securities

 

The following represents all unregistered securities issued by the registrant during the current period, including sales of reacquired securities, as well as new issues, securities issued in exchange for property, services, or other securities, and new securities resulting from the modification of outstanding securities:

 

On January 23, 2017, in connection with a certain subscription agreement, the Company issued 30,000 shares of its Series B Preferred Stock at $5.00 per share to a related party, for cash in the amount of $150,000. The shares are convertible into common stock at a ratio of 20 common shares for each preferred share held and include 50% warrant coverage at an exercise price of $0.75 for a period of two (2) years.  Dividends are payable semi-annually at a rate of 10% per annum.

 

On March 16, 2017, in connection with a certain related party convertible promissory note in the amount of $250,000 and accrued interest of $7,954, the Company issued 1,228,346 shares of its restricted common stock at a conversion rate of $0.21 per share.

 

On May 17, 2017, in connection with the ProEventa Agreement dated April 26, 2017, the Company issued 2,500,000 shares of its restricted common stock. The shares, valued at $625,000, were issued for cash in the amount of $2,500.

 

On May 17, 2017, in connection with a certain consulting agreement dated April 26, 2017, the Company issued 500,000 shares of its restricted common stock to the consultant for cash in the amount of $500, for services to be provided over a thirty-six (36) month period.  The shares were valued at $125,000, of which $6,916 was expensed, and $117,854 was deferred, to be amortized over the next thirty-five (35) months.

 

On May 18, 2017, in connection with a certain related party convertible debt in the amount of $200,000 and accrued interest of $27,781, the Company issued 2,277,808 shares of its restricted common stock at a conversion rate of $0.10 per share.

 

On June 2, 2017, in connection with the exercise of certain employee stock options, the Company issued 237,500 shares of its restricted common stock at a conversion rate of $0.05 per share.  The shares were issued on a cashless basis, resulting in a net value of $57,000.

On July 1, 2017, in connection with a certain consulting agreement, the Company issued 1,500,000 shares of its restricted common stock to the consultant for services to be provided over a twelve (12) month period.  The shares were valued at of $315,000, of which $78,750 was expensed, and $236,250 was deferred, to be amortized over the next twelve (12) months.

 

On July 7, 2017, in connection with a certain executive employment agreement, the Company granted the executive 10,000,000 shares of its restricted common stock at $0.001 per share, of which 25% vest immediately, and the remaining vest over a period of twenty-four (24) months.  The shares were valued at $2,000,000, of which $507,500 was expensed, and $1,492,500 was deferred, to be amortized over the next twenty-four (24) months.

 

On July 21, 2017, in connection with a certain consulting agreement, the Company issued 1,000,000 shares of its restricted common stock to the consultant for services rendered.  The shares were valued at $270,000.

 

On August 1, 2017, in connection with a certain executive employment agreement, the Company issued 3,000,000 shares of its restricted common stock at $0.001 per share.  The shares were valued at $750,000.

 

On August 3, 2017, in connection with the exercise of certain employee stock options, the Company issued 44,102 shares of its restricted common stock at a conversion rate of $0.05 per share.  The shares were issued on a cashless basis, resulting in a net value of $10,584.

 

On August 9, 2017, in connection with a certain debt settlement, the Company issued 100,000 shares of its restricted common stock to a consultant as partial payment for services rendered. The shares were valued at $15,000.

 

On September 1, 2017, in connection with certain consulting agreements, the Company issued 250,000 shares of its restricted common stock to the consultants for services to be provided over a twelve (12) month period.  The shares were valued at $50,000, which was deferred, to be amortized over the next twelve (12) months.

 

On September 11, 2017, in connection with a certain related party convertible debt in the amount of $40,000, the Company issued 400,000 shares of its restricted common stock at a conversion rate of $0.10 per share.

 

On October 4, 2017, in connection with a certain consulting agreement, the Company issued 200,000 shares of its restricted common stock to the consultant for services to be provided over a twelve (12) month period.  The shares were valued at $38,000, of which 25% vest immediately, and the remainder vest monthly over the first three (3) months of the agreement.  As  a result, $9,500 was expensed, $28,500 was deferred, to be amortized over three (3) months.

 

Between November 14, 2017 and December 13, 2017, in connection with an equity offering, the Company issued 3,950,000 shares of its restricted common stock at a price of $0.05 per share, for cash in the amount of $197,500.

 

On December 4, 2017, in connection with a certain settlement for debt in the amount of $87,500 and interest in the amount of $12,500, the Company issued 2,000,000 shares of its restricted common stock at a rate of $0.05 per share.

 

On December 15, 2017, in connection with a certain consulting agreement, the Company issued 500,000 shares of its restricted common stock to the consultant for services to be provided over a twelve (12) month period.  The shares were valued at $51,250, of which 60% vest immediately, and the remainder vest periodically over the term of the agreement.  As a result, $30,750 was expensed, $20,500 was deferred, to be amortized over the next twelve (12) months.  

 

During the year ended December 31, 2017, a total of $2,838,500 in deferred stock compensation was recorded, of which $1,028,498 was expensed. As of December 31, 2017, there remains $1,810,002 in deferred stock compensation to be expensed over the next thirty-three (33) months.

 

Exemption From Registration. The shares of Common Stock referenced herein were issued in reliance upon an exemption from registration afforded either under Section 4(2) of the Securities Act for transactions by an issuer not involving a public offering, or Regulation D promulgated thereunder, or Regulation S for offers and sales of securities outside the U.S.

 

ITEM 6.SELECTED FINANCIAL DATA  

 

As a “smaller reporting company”, the Company is not required to provide the information required by this Item.


Table of Contents

- 25 -



ITEM 7.MANAGEMENTS DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS 

 

Forward-Looking Statements

 

This annual report contains forward-looking statements. These statements relate to future events or the Company’s future financial performance. In some cases, forward-looking statements can be identified by terminology such as "may", "should", "expects", "plans", "anticipates", "believes", "estimates", "predicts", "potential" or "continue" or the negative of these terms or other comparable terminology. These statements are only predictions and involve known and unknown risks, uncertainties and other factors that may cause the Company’s or the Company’s industry's actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, the Company cannot guarantee future results, levels of activity, performance or achievements. Except as required by applicable law, including the securities laws of the United States, the Company does not intend to update any of the forward-looking statements to conform these statements to actual results.

 

The Company’s audited consolidated financial statements are stated in United States Dollars and are prepared in accordance with United States Generally Accepted Accounting Principles.

 

Corporate History

 

The Company was incorporated in the State of Nevada on July 6, 2005.  On November 1, 2012, the Company, formerly Endeavor Power Corporation, and its wholly-owned subsidiary Endeavor Holdings, Inc., a Nevada corporation, entered into an Agreement and Plan of Merger with Parallax Diagnostics, Inc., a Nevada corporation ("Parallax Diagnostics"), whereby Parallax Diagnostics became a wholly-owned subsidiary.  On January 9, 2014, the Company changed its name to Parallax Health Sciences, Inc. (“Parallax”).  (OTCQB.PRLX).

 

Parallax’s current family of companies that serve as the foundation for its cross-over business model of operations include:

 

Parallax Diagnostics, Inc. ("Parallax Diagnostics" or "PDI") is the Company’s point of care diagnostic testing company focused on the exploitation of a proprietary diagnostic immunoassay testing platform and test cartridges for the areas of infectious diseases, cardiac markers, drugs of abuse and various other medical conditions. Parallax’s primary focus is to commercialize the Target System worldwide.  Parallax Diagnostics is currently pre-revenue and continues to pursue viable opportunities for the commercialization of its product.   

 

The commercial and clinical proposition of Parallax Diagnostics’ Target System is based on:

 

The Target System will allow doctors to test patients in their office; and 

The Target System is one-time learning process to perform all of its tests; and 

The Target System delivers test results in 10 minutes or less providing patients with important information at the time of testing; and 

The Target System costs less than outside lab-based tests allowing payers to pay less, a reduction in patient co-pays; and 

Allows doctors to earn additional revenue that they cannot participate in with outside labs and testing not performed in their offices. 

 

The Company has sought to identify strategies that would make its proposition more valuable and competitive.  To this end, the Company has pursued the creation of patents around its foundational technology and developed a novel immune status test targeting the HIV/AIDS and TB markets. Since the inception of Parallax Diagnostics, the novel CD4-CD8 immune status test has been developed, and the Company has been issued patents on elements of its core technology and testing system.

 

Parallax Health Management, Inc. (formerly Qolpom, Inc.) (“PHM”) a Tucson, Arizona based Remote Patient Monitoring (“RPM”) business is the Company’s most recent acquisition, and represents an opportunity to develop products and services, and commercialize them, on a proprietary platform, in the RPM and Telehealth market, that will allow for systems integration with a number of third party services and solutions. In 2016, PHM initiated the generation of revenue through the deployment of its services and products. 

 

The commercial and clinical proposition of PHM is based on the following propositions:

 

Improve digital connectivity among consumers, providers, health plans, and life sciences companies; and  

Facilitate self-managed care, with the help of technology-enabled solutions, in a secure environment that `protects consumer privacy; and  

Deliver care outside the traditional clinical setting, potentially providing better access to care at a lower cost.  

Assist chronic care management and improve population health outcomes; and 

PHM empowers patients by providing a cost-effective tool that connect them with their doctors; and 

PHM empowers doctors with improved patient scheduling flexibility and timely communications; and 

PHM provides hospitals with a tool to address the problem and economic hardship caused by readmissions; and 

PHM provides a virtual management tool for chronic disease management. 

 

Parallax Behavioral Health, Inc. (“PBH”), a Delaware corporation, was formed by the Company in March 2017, and acquired the intellectual property known as REBOOT, the acronym for Reliable Evidence-Based Outcomes Optimization Technologies.  In 2018, the Company rebranded the technology as Intrinsic Code (“Intrinsic Code”), a software platform specifically designed to improve health treatment outcomes through Internet-based and mobile behavioral technology systems that enable its users and user groups to more effectively achieve goals within a prescribed timeline. The Intrinsic Code technology and software platform can be used by an individual or an organization of any size, with the potential to transform the cost of treating and managing chronic illnesses such as pulmonary-COPD-asthma, diabetes, and cardiovascular disease by effecting the modification of behavior in patients being treated for these chronic diseases. 

 

The Company is currently implementing its development and marketing strategies to integrate the Intrinsic Code technology within the Parallax family of healthcare products and services.

 

RoxSan Pharmacy, Inc. (“RoxSan”), acquired in the 3rd quarter of 2015, is the Company’s 62-year-old, Beverly Hills, California based compound pharmacy that is licensed to operate in over 40 States.  


- 26 -



Acquisition of RoxSan Pharmacy, Inc.

 

In 2013, Parallax identified an opportunity to acquire RoxSan Pharmacy, Inc. ("RoxSan"), a California corporation, and began the due diligence process.  The Company's initial interest centered on utilizing the acquisition as a means of accelerating the commercialization of the Parallax Target System and diagnostic platform, as RoxSan had access to a nationwide network of doctors and sales representatives.  During the due diligence process, the Company became aware of the numerous opportunities that RoxSan and its markets represented.

 

On March 21, 2013, the Company entered into a Letter of Intent with Shahla Melamed, RoxSan's sole Shareholder, to acquire RoxSan.  Between 2013 and 2015, four (4) amendments were also executed.

 

As part of the acquisition, the Company was required to obtain licensure from the State of California, and on July 31, 2015, the Company received notice that its pharmacy and sterile compounding licenses were issued by the California State Board of Pharmacy.

 

On August 13, 2015 (the "Closing Date"), pursuant to a resolution of the board of directors (the "Board"), the Company entered into an Agreement to Purchase and Sell One Hundred Percent of the Issued and Outstanding Shares of RoxSan Pharmacy, Inc. ("RoxSan" or the "Pharmacy"), and its Assets and Inventory (the “Purchase Agreement”).  Pursuant to the Purchase Agreement between the Company, RoxSan and its sole shareholder, Shahla Melamed (the “Seller” or "Melamed"), in exchange for 100% of RoxSan's common stock, and its assets and inventory, the Company, among other things, issued the Seller a Secured Promissory Note (the "Note") dated August 13, 2015 in the amount of $20.5 million (the "Acquisition").  The Note bears interest at a rate of 6% per annum, and matures in three (3) years, or August 13, 2018 ("Maturity").  The Company is seeking a reduction in the Purchase Price and related promissory note (See Legal Proceedings).  As a result of the Acquisition, effective August 13, 2015, RoxSan became a wholly-owned subsidiary of the Company. No change in control of the Company occurred as a result of the Acquisition.

 

In connection with the Acquisition, the Company entered into an Employment Agreement (the "Employment Agreement") with the Seller.  Under the Employment Agreement, Melamed agreed to provide exclusive consulting services to the Company in the areas of public relations and marketing for a term of four (4) years. On March 4, 2016, the Company terminated the Employment Agreement in accordance with paragraph 3.2 Termination for Cause.  The termination was the result of, among other things, Melamed's breaches in the Agreement, which were substantiated by an investigation conducted by an employment law firm retained by RoxSan.  Under the terms of the Agreement, no financial obligation resulted in the termination. (see "Dispute with Former Owner" below).

 

Closure of RoxSan Pharmacy.

 

Since the Company’s acquisition of RoxSan, the deleterious actions against the pharmacy by the former owner, including, among other things, interference with management and operations, and attempts to damage and/or divert customer and vendor relationships, had a significant adverse impact on the pharmacy. Furthermore, the discovery of the former owner’s alleged involvement in suspected insurance fraud caused RoxSan’s contract with its primary IVF drug rebate program to be terminated in August 2016. As a result, RoxSan was no longer eligible to receive incentive rebates for the majority of its IVF drug purchases, which were key to the profitability of the IVF drug sales; and for which without the rebates, RoxSan was unable to provide its customers with comparably priced IVF drugs.  This, among other things, caused a precipitous drop in RoxSan’s IVF revenues, and ultimate exit from the IVF market in mid-2017.  Soon thereafter, in July 2017, RoxSan’s contract with its primary drug supplier was terminated for similar reasons connected to the former owner and alleged criminal activities associated with the Melamed family name, despite the Company’s new ownership and management. After careful consideration, the Company determined that RoxSan was unable to generate enough profits to sustain its pharmacy business, and in December 2017, the pharmacy ceased operations.

 

On May 14, 2018, pursuant to a unanimous resolution of the Boards of Directors of RoxSan Pharmacy, Inc. and Parallax Health Sciences, Inc., RoxSan filed a Chapter 7 petition in the United States Bankruptcy Court for the Central District of California.  Mr. Timothy Yoo was appointed trustee on May 15, 2018.  In connection with this filing, RoxSan seeks to discharge approximately $5 million of liabilities owed to various parties including more than $1 million owed to the Company.

 

Acquisition of Parallax Health Management, Inc, (formerly Qolpom, Inc.)

 

As part of the Company’s strategic plan to obtain a platform to enhance its diagnostic tests, on August 31, 2016 (the “Execution Date”), the Company entered into an agreement with Qolpom, Inc., an Arizona corporation in the remote healthcare monitoring and telehealth business (“Qolpom”) and its shareholders (the “Seller”) to purchase 100% of the issued and outstanding shares of Qolpom’s common stock and its assets, inventory and intellectual property.  The Purchase Agreement was fully executed on September 20, 2016, and the transaction was completed (the “Closing Date”). The Qolpom name was later changed to Parallax Health Management, Inc. (“PHM”).

 

Pursuant to the Qolpom Agreement, in exchange for 100% of the Qolpom stock and 100% of Qolpom’s assets, inventory and intellectual property, among other things, consideration to the Seller included:

 

5,000,000 shares of the Company’s common stock; and 

2,500,000 options to purchase shares of the Company's common stock, to be granted one year from the Execution Date, and vesting over three (3) years, of which 500,000 are exercisable at $0.10, 1,000,000 are exercisable at $0.15, and 1,000,000 are exercisable at $0.25; and 

10% of revenues generated from PHM business segment, up to $1,000,000; and 7% thereafter, up to $2,000,000; and 

3% of revenues generated from the sale of Qolpom hardware and monitoring service fees. 


Table of Contents

- 27 -



Formation of Parallax Behavioral Health, Inc.

 

On March 22, 2017, the Company formed a wholly-owned subsidiary, Parallax Behavioral Health, Inc. (“PBH”), a Delaware corporation.

 

On April 26, 2017, pursuant to a resolution of the board of directors, the Company and its wholly-owned subsidiary, Parallax Behavioral Health, Inc., completed the acquisition of 100% of certain intellectual property from ProEventa Inc., a Virginia Corporation (“ProEventa”), in accordance with the Intellectual Property Purchase Agreement between the Company, PBH and ProEventa (the “ProEventa Agreement”). ProEventa has an expertise in the development of behavioral health technologies, and is the wholly-owned subsidiary of Grafton Integrated Health Network, Inc., a non-profit Virginia corporation (“Grafton”), Pursuant to the ProEventa Agreement, in exchange for 100% of that certain intellectual property, among other things, consideration to ProEventa included:

 

a stock purchase agreement to purchase 2,500,000 shares of the Company’s common stock; and 

a revenue sharing agreement, providing for a cash earn-out to be paid to the ProEventa shareholders of up to $3,000,000, to be derived from certain net revenue generated by the Company, as defined in the agreement; and 

a royalty agreement, providing for a royalty of 3% of the revenues generated from the intellectual property, ending at such time as Parallax has paid ProEventa $25,000,000; and 

a limited license to ProEventa for the use of certain of the Intellectual Property's technology at Grafton Schools. 

 

On April 26, 2017, in conjunction with the ProEventa Agreement, the Company entered into a consulting agreement with James Gaynor that, among other things, provides for consideration to Mr. Gaynor as follows:

 

a stock purchase agreement to purchase 500,000 shares of the Company’s common stock at $0.001 per share; and 

a grant of options to purchase 1,000,000 shares of the Company's common stock at a price of $0.25 per share, vesting annually over a three (3) year period beginning September 1, 2017. 

 

Changes in Management

 

On December 29, 2016, Mr. John L. Ogden and Ms. Calli R. Bucci were elected to serve as members of the Company's board of directors.

 

On April 6, 2017, the Board elected Mr. J. Michael Redmond as Chairman, to serve until the Company’s next meeting, in accordance with the Company's bylaws, or a resignation is duly tendered.

 

Effective July 6, 2017, the Board of the Company caused the departure of Mr. Redmond from his position as President and Chief Executive Officer of the Company and its wholly-owned subsidiary, RoxSan Pharmacy, Inc. Pursuant to the Employment Agreement dated August 1, 2015, a resignation from the Board of the Company and its wholly-owned subsidiaries, RoxSan Pharmacy, Inc. and Parallax Health Management, Inc. was tendered automatically.

 

Effective July 7, 2017, pursuant to a unanimous Board resolution, Mr. Paul R. Arena was appointed as the Company’s President and Chief Executive Officer, and the Board caused Mr. Arena's election to the Company's Board and the Board of its wholly-owned subsidiaries, RoxSan Pharmacy, Inc. and Parallax Health Management, Inc.

 

On July 7, 2017, in connection with Mr. Arena’s appointment, the Company entered into an Executive Employment Agreement (the “Agreement”) with Mr. Arena dated July 7, 2017, wherein Mr. Arena will serve as President and Chief Executive Officer for a period of three (3) years.  As compensation for his services, Mr. Arena will receive a base compensation of $350,000 in year one, of which 30% shall be deferred until certain funding goals are met, $425,000 in year two, and $550,000 in year three, as well as annual bonus compensation equal to 2x base when certain Company earnings are reached.  In addition, the Agreement includes a grant to purchase 10,000,000 restricted common shares at $0.001 per share, of which 25% vests immediately; 25% vests in one year; 25% vests after two years; and 25% vests when certain funding goals have been met.  The shares were valued at $2,000,000, of which $500,000 was expensed, and $1,500,000 was deferred, to be amortized over the next thirty-six (36) months. The Agreement also includes the grant of 5,000,000 stock options at an exercise price of $0.25 per share.  The options are exercisable for a period of five years, and vest when certain market share prices of the Company’s common stock are met.

 

On July 26, 2017, Mr. Jorn Gorlach resigned as a member of the board of directors.  This resignation did not involve any disagreements with the Company.

 

On June 4, 2018, Mr. Anand Kumar resigned as a member of the board of directors.  This resignation did not involve any disagreement with the Company.  Mr. Nathaniel T. Bradley, currently serving as Chief Technology Officer, succeeds him; to serve as a member of the board of directors until the next annual meeting of the shareholders and/or until his successor is duly appointed.

 

Dispute with Former Owner of RoxSan

 

Shortly after the Closing, the Company's management and Melamed clashed over control of the RoxSan Pharmacy business operations and bank accounts.

 

Purchase Price Dispute 

Included in the Acquisition Agreement, and as part of the negotiated purchase price, were representations and warranties made by the former owner involving certain primary revenue streams and related contracts.  Shortly after the closing, however, management discovered that these representations were substantially inaccurate and/or completely false.  These inaccuracies, and the improper disclosures and/or omissions made by the former owner during negotiations, would have significantly affected the purchase price and related note payable.  As a result, among other things, management has initiated legal action against the former owner to seek a reduction in the purchase price.

 

In addition, management engaged a third-party to perform a valuation of the pharmacy, utilizing revised inputs that more accurately reflected the Pharmacy's revenue streams as of the date of Acquisition.  The valuation performed resulted in a fair market value of $4.7 to $5.2 million. After careful consideration, and based upon these significant differences, management has determined that the purchase price and related promissory note of $20.5 million does not fairly represent the fair market value at the date of purchase.  The Company has, therefore, applied a discount to the note of $15.3 million, to reduce the purchase price and related note to its estimated fair market value of $5.2 million, utilizing the higher value on the range of as a conservative measure.

 

The valuation performed does not include the effects of any liabilities the former owner omitted or damages caused to the Company as a result of the former owner and her immediate family members connected to the Pharmacy.

 

Control of Funds Dispute / US Postal Service Interference 

For a period of time immediately after the closing of the Acquisition, the former owner would not relinquish control of the Pharmacy's bank accounts, and collected the Pharmacy's incoming cash revenues, refusing to transfer the funds to the new ownership. Furthermore, when the Company attempted to change the corporate records and signatories on the existing bank accounts, the former owner disputed the changes, resulting in approximately $180,000 in corporate funds being frozen and held for adjudication. During this period, the Company was forced to request that the former owner pay the Pharmacy's operating expenses.  At no time after the Company opened new accounts did the former owner cooperate with the transference or willingly relinquish control of the Pharmacy's operating cash flow or incoming cash revenues.

 

The former owner continued to interfere in the transference of control of the Pharmacy by submitting change of address forms to the US Postal Service, wherein the former owner diverted the Pharmacy mail to her home address.  Once this was discovered and rectified with the post office, the former owner filed another change of address to divert mail to a post office box.  During these periods of time, the former owner received check payments and negotiated the checks by opening up a bank account utilizing a DBA, "Roxsan Pharmacy."  The Company was able to identify some of the checks the former owner negotiated by directly contacting the payer and receiving copies of the cancelled checks, with the former owner's signature endorsement and account number on the check.

 

As a result, an extensive reconciliation was performed to determine what amounts were collected and paid by the former owner, and what amounts were due to the Company.  The reconciliation resulted in over $412,000 owed to the Company from the former owner.  The reconciliation and underlying documentation went under judicial review, and on July 24, 2017 the Company was notified that the results of the review were in favor of the Company in the amount of $412,948.  A final judgment is pending for the exact amount of monies owed to the Company from the former owner.


- 28 -



Faced with Melamed continuing to materially interfere with the Pharmacy’s operations to the detriment of its business, the Company retained the services of an employment law firm to investigate Melamed's actions and provide a report to the Company’s Board (the "Report").  The Company also placed Melamed on a paid leave of absence because of her actions. The Board, after reviewing the findings in the Report, found substantive cause for Melamed's termination, and immediately sent Melamed written notification of the Company's intent to dismiss her for cause.  Under the Employment Agreement, Melamed was provided with a thirty (30) day cure period.  However, the Company received no response of intent to cure from Melamed or her counsel, and no evidence of a cure was provided to the Company.  As a result, the Board authorized Melamed's termination for cause on March 3, 2016, and on March 6, 2016, Melamed was formally terminated in writing.

 

In the course of management’s operation of the RoxSan Pharmacy, and adherence to Financial Accounting Standards Board revenue recognition policies, management became concerned with the absence of the claim processing for over $16 million of pre-Close Workers Compensation prescription revenues, which Melamed represented to the Company prior to Closing as being the vast majority of the high margin compound revenue. In addition to the $16 million in pre-Close claims, the Pharmacy generated over $8 million after the change in ownership, until the CFO alerted management of a serious and dramatic change in the receivables collection timetable, the underpinning cash flow processes, and the potential illegitimacy of the Workers Compensation revenues. Further, the CFO was uncomfortable with recognizing the revenue as it was presented by Melamed's financial records, and, in the absence of any reasonable assurance of collectability of the Workers Compensation revenues, the Company established an allowance for doubtful receivables for the $8 million in post-Close claims for which collectability was highly unlikely.

 

The Company retained the services of a forensic Workers Compensation fraud specialist to determine the legitimacy of the pre-Close Workers Compensation revenues and related insurance claims.  As a result of this forensic review, it was determined that these claims were essentially valueless.  As a result of these findings and undisclosed changes to the cash flow and quality of earnings that represented a majority of the revenue of the Pharmacy, the Company’s Board deemed it necessary to demand a reduction in the terms of the Sale and Purchase Agreement to more accurately reflect the true valuation of the Company.  This was met with resistance on the part of the Seller.

 

Shortly thereafter, in October 2015, Melamed, initiated two (2) legal actions against the Company in the Superior Court of the State of California, County of Los Angeles, West District, Shahla Melamed v. Parallax Health Sciences, Inc., action numbers SC 124873 and SC 125702.

 

In the matter, action No. SC 124873, Melamed sought rescission of the August 13, 2015 Purchase Agreement. During the proceedings, Melamed also contended that the Company owed Melamed monies for, among other things, expenses paid by Melamed on behalf of the Company.  As a result, the Court split the action into two separate rulings: (1) Rescission Phase and (2) Accounting Phase.

 

Rescission Phase  -  Final Ruling:  On March 17, 2017, the Court ruled in favor of the Company, and issued that Melamed is not entitled to rescission of the Purchase Agreement.  The ruling of the Court stated that no fraud on the part of the Company or its principals had been demonstrated.  The Court further ruled that there had been no failure of consideration, and that Melamed’s entry into the Agreement was not a result of a unilateral mistake on the part of Melamed.  The Minutes of the Ruling were entered by the County Clerk on March 17, 2017. 

 

Accounting Phase  -  Draft Ruling: On July 24, 2017, in the Matter, action No. SC124873, the Company was notified that the results of the reconciliation review performed by third-party adjudicator were in favor of the Company in the amount of $412,948.  Melamed objected to the adjudicator’s findings, and a final hearing was held in January 2018.  A final judgment is pending for the Court’s decision on the exact monies owed by Melamed to the Company. 

 

In the Matter, action No. SC125702, Melamed alleges that the Company is in default under the terms of the Purchase Agreement and Secured Note and the Company’s termination of Melamed’s employment agreement.  The Company firmly believes that it had adequate grounds to justify the termination of the employment, that it acted within its rights, and shall prevail in these proceedings.

 

The Company has initiated legal action against Melamed and filed a complaint, action number SC 124898, in the Superior Court of the State of California, County of Los Angeles, West District, Parallax Health Sciences, Inc., et al. v. Shahla Melamed, et al.  The Complaint in that action alleges that Melamed has breached several obligations under the Purchase Agreement, and the Company is seeking to reduce the Secured Note due to undisclosed material changes in the business.

 

On May 14, 2018, pursuant to a unanimous resolution of the Boards of Directors of RoxSan Pharmacy, Inc. and Parallax Health Sciences, Inc., RoxSan filed a Chapter 7 petition in the United States Bankruptcy Court for the Central District of California.  Mr. Timothy Yoo was appointed trustee on May 15, 2018.  In connection with this filing, RoxSan seeks to discharge approximately $5 million of liabilities owed to various parties including more than $1 million owed to the Company.

 

Disputes with Former Executives

 

On March 9, 2017, Mr. Dave Engert filed a lawsuit in Arizona and then on or about May 5, 2017, Mr. Engert, changed the venue and filed suit against the Company and RoxSan Pharmacy, Inc. in the United States District Court, Central District of California for an amount exceeding $75,000.  The Company intends to vigorously defend against this action, and on October 23, 2017, filed an answer and counterclaims against Mr. Engert for an amount exceeding $100,000.  The counterclaims include possible fraud and negligence committed by Mr. Engert and Mr. J. Michael Redmond, former successor Chairman of Mr. Engert, director, President and Chief Executive Officer of the Company and former President, Chief Executive Officer, Chairman and director of RoxSan Pharmacy, Inc.

 

On March 28, 2018, Mr. J. Michael Redmond filed a lawsuit against the Company and RoxSan Pharmacy, Inc. in the United States District Court, Central District of California for an amount exceeding $75,000.  The Company intends to vigorously defend against this action. There are counterclaims that include possible fraud and negligence committed by Mr. Redmond, former successor Chairman of Mr. Engert, director, President and Chief Executive Officer of the Company and former President, Chief Executive Officer, Chairman and director of RoxSan Pharmacy, Inc.

 

For additional information on these proceedings, see “ITEM 3. LEGAL PROCEEDINGS” section contained within this annual report.


Table of Contents

- 29 -



Description of Business  

 

Parallax Health Sciences, Inc. is an innovative biomedical health-care company headquartered in Santa Monica, California, which operates under three divisions: Medical Diagnostics, Pharmaceuticals, Remote Health Care, and Behavioral Health Systems. Each of these divisions target a separate vertical market that are synergistic, compliment, and strengthen each other and the Parallax value proposition as a whole.

 

The Parallax Business Model

 

In the past 60 years, healthcare has transitioned from a direct relationship between doctor and patient, to one that has patients separated from their doctors by the introduction of a huge number of stakeholders, ranging from health insurers, employers, pharmacy benefit managers, imaging, diagnostic testing, lawyers, specialist and a plethora of others.  The patient and healthcare provider both want the same thing: information, quality of service, transparency, value for their hard-earned dollars, and more time in their day.

 

Parallax believes that its products and services can provide solutions that mitigate rising costs, reduce waste in spending through transparency, reduce the amount of unnecessary services, and increase the health and wellness of patients before they are sick.

 

Parallax has developed, acquired and licensed multiple platforms, proprietary and exclusive, that provide services and products, across the healthcare continuum.  These platforms are designed to allow for multiple points of reciprocal consideration, through innovative business models, that provide patients with increased quality of services and products, at reduced cost of time and money.  They also provide healthcare providers with increased access to their patients, the ability to deliver better and more efficient service and increase their income from the services they supply.

 

Although Parallax’s multiple operations are focused in separate vertical markets, Parallax has designed its business model to allow for cross-pollination and reciprocal transfer of value at multiple points in their respective economic food chains.

 

Management

 

Parallax is led by experienced veterans from the healthcare, technology, finance and management fields.  The Company's disciplined and organized approach is balanced by its optimism for the future, and the opportunities present in the current healthcare market. The Parallax team is grounded in a belief that success in business is built on a combination of research, planning and execution.

 

Operating Segments

 

The Company's business operations generated revenue through multiple economic models, ranging from cash payments, insurance reimbursements and pharmaceutical drug rebates derived from its compounding, retail and fertility business, to PHM’s initial remote patient monitoring activity, the deployment of its Good Health Outcomes Platform, integration of Intrinsic Code technology, and the sale of third-party vendor devices.

 

During 2017, the Company operated the following four (4) segments:

 

Pharmacy 

 

RoxSan provides a full range of pharmacy services including retail, compounding and fertility medications.  RoxSan generates net revenues primarily by dispensing prescription drugs, both through local channels by direct delivery as well as mail order. RoxSan also sells a wide assortment of general merchandise, including over-the-counter drugs, beauty products and cosmetics, seasonal merchandise and convenience foods, through the Company’s pharmacy. The pharmacy is fully licensed and qualified to conduct business in over 40 US States.

 

Since the Company’s acquisition of RoxSan, the deleterious actions against the pharmacy by the former owner, including, among other things, interference with management and operations, and attempts to damage and/or divert customer and vendor relationships, had a significant adverse impact on the pharmacy. Furthermore, the discovery of the former owner’s alleged involvement in suspected insurance fraud caused RoxSan’s contract with its primary IVF drug rebate program to be terminated in August 2016. As a result, RoxSan was no longer eligible to receive incentive rebates for the majority of its IVF drug purchases, which were key to the profitability of the IVF drug sales; and for which without the rebates, RoxSan was unable to provide its customers with comparably priced IVF drugs.  This, among other things, caused a precipitous drop in RoxSan’s IVF revenues, and ultimate exit from the IVF market in mid-2017.  Soon thereafter, in July 2017, RoxSan’s contract with its primary drug supplier was terminated for similar reasons connected to the former owner and alleged criminal activities associated with the Melamed family name, despite the Company’s new ownership and management. After careful consideration, the Company determined that RoxSan was unable to generate enough profits to sustain its pharmacy business, and in December 2017, the pharmacy ceased operations.

 

Remote Patient Monitoring  

 

PHM provides a first-of-its-kind technology platform that provides for the complete remote patient care delivery system: the patent-pending Good Health Outcomes, which utilizes proprietary software and technology to bridge clinical behavioral science with technology and logistics for payers, providers and clinical professionals across a variety of wellness and clinical devices, including both fitness and clinical applications. PHM’s Good Health Outcomes is a secure and scalable platform for collecting, transmitting and analyzing biometric, pharmaceutical, and health data to healthcare providers, primarily hospitals, accredited nursing operations, and physicians.

 

PHM generates revenues through fees charged for the license and utilization of its proprietary system that provides software integrations of the Good Health Outcomes platform.  Additionally, PHM generates incremental revenues through the delivery of acute, post-acute and chronic health patient management software systems that enable PHM customers to bill for and collect payments from patients and third-party payers for telemonitoring and remote services that they deliver.

 

Behavioral Health Systems 

 

In April 2017, the Company, through its wholly-owned subsidiary, Parallax Behavioral Health, Inc., acquired the intellectual property known as REBOOT, the acronym for Reliable Evidence-Based Outcomes Optimization Technologies.  In 2018, the Company rebranded the technology as Intrinsic Code (“Intrinsic Code”), a software platform specifically designed to improve health treatment outcomes using proprietary behavioral technology systems, that enables its users and user groups to more effectively achieve goals within a prescribed timeline. Through a proprietary behavioral health technology, Intrinsic Code powers decision support that can also be delivered securely to any internet connected device. The software can be used by an individual or an organization of any size.

 

PBH generates revenues primarily through licensing and subscription of the Intrinsic Code software and systems. As of December 31, 2017, the BHS segment had not yet begun full operations, generating limited test market sales.

 

Corporate  

 

The Corporate Segment provides management and administrative services to support the Company and consists of certain aspects of the Company’s executive management, corporate relations, legal, compliance, human resources, and corporate information technology and finance departments.  In addition, the Corporate Segment supports the costs and operating expenses related to the continued development and exploitation of the Company's proprietary medical diagnostic and monitoring platform and processes, which remains the Company's primary focus.


- 30 -



NOTE: The following sections of this annual report and any further reference made to “the Company”, "we", "us", "our" and "Parallax " shall mean Parallax Health Sciences, Inc., and its wholly-owned subsidiaries, Parallax Diagnostics, Inc., Parallax Health Management, Inc. (formerly Qolpom, Inc.), RoxSan Pharmacy, Inc., and Parallax Behavioral Health, Inc. unless otherwise indicated.

 

Balance Sheet

 

As at December 31, 2017, the Company had total assets of $3,340,475, compared with total assets of $2,623,991 at December 31, 2016. The increase in total assets of $716,484 is attributable to a decrease in cash of $60,759, a decrease in accounts receivable, net of allowance for doubtful accounts of $721,654, a decrease in rebates receivable of $72,030, a decrease in inventories of $410,148, a decrease in employee advances of $9,202, a decrease in prepaid expenses of $85,981, an increase in intangible assets of $2,422,500, $29,359 of depreciation related to equipment, $316,133 of amortization related to intangible assets, and a decrease in deposits of $750.

 

As at December 31, 2017, the Company had total liabilities of $30,730,119, compared with total liabilities of $20,197,872 at December 31, 2016. The increase in total liabilities of $10,532,247 is attributable to an increase in accounts payable and accrued expenses of $1,983,116, an increase in pension plan contribution payable of $1,748, an increase in convertible notes payable of $741,000, an increase in related party payables of $964,440, an increase in license fees and royalties payable of $1,800,000, a decrease in related party convertible notes payable of $190,000, a decrease in secured notes payable of $182,324, and a decrease in unamortized discount of $5,450,000.

 

Results of Operations

 

The following summary of the Company’s results of operations should be read in conjunction with the Company’s audited consolidated financial statements for the years ended December 31, 2017 and 2016, which are included herein. The financial information provided includes the accounts of the Company and its wholly-owned subsidiaries, Parallax Diagnostics, Inc., RoxSan Pharmacy, Inc., Parallax Health Management, Inc. (formerly Qolpom, Inc.), and Parallax Behavioral Health, Inc., on a consolidated basis.  All significant inter-company accounts and transactions have been eliminated.

 

 

For the year ended

 

 

December 31, 2017

 

December 31, 2016

 

Revenue

$

3,195,144

 

$

22,749,087

 

Cost of sales

$

3,226,247

 

$

19,187,944

 

Gross profit (loss)

$

(31,103

)

$

3,561,143

 

Sales, marketing, and pharmacy expenses

$

660,400

 

$

1,825,900

 

General and administrative expenses

$

6,426,976

 

$

4,882,134

 

Operating (loss)

$

(7,118,479

)

$

(3,146,891

)

Impairment loss

$

––

 

$

(4,016,924

)

Discount amortization

$

(5,450,000

)

$

(5,100,000

)

Interest expense, net of interest/dividend income

$

(1,308,027

)

$

(918,044

)

Net loss

$

(13,876,506

)

$

(13,181,859

)

 

Revenue

 

Revenue in the amount of $3,195,144 for the year ended December 31, 2017 consists of pharmaceutical sales related to the Company's pharmacy operations in the amount of $3,100,207, contract fees and equipment sales related to the Company’s remote healthcare services in the amount of $93,737, and subscription income related to the Company’s behavioral health software in the amount of $1,200.

 

Revenue in the amount of $22,749,087 for the year ended December 31, 2016 consists of pharmaceutical sales related to the Company's pharmacy operations in the amount of $22,701,221, and contract fees and equipment sales related to the Company’s remote healthcare services in the amount of $47,866 for the period September 20, 2016 through December 31, 2016.

 

In August 2016, the Company’s contract with its primary In Vitro Fertilization (“IVF”) drug rebate program was cancelled, resulting in a 94.5% reduction in IVF revenues.  The total IVF revenues for 2017 and 2016, respectively, were $953,680 and $17,216,036, or 29.8% and 75.7% of total revenues.

 

The Company has not yet launched its major business activity, which is medical diagnostics and testing.

 

Cost of sales

 

Costs of sales in the amount of $3,226,247 for the year ended December 31, 2017 consists of pharmaceutical drug purchases, direct labor, and indirect pharmacy costs related to the Company's pharmacy operations in the amount of $3,084,205, and equipment and other costs related to the Company’s remote healthcare systems in the amount of $142,043.

 

Costs of sales in the amount of $19,187,944 for the year ended December 31, 2016 consists of pharmaceutical drug purchases, direct labor, and indirect pharmacy costs related to the Company's pharmacy operations in the amount of $19,163,102, and equipment and other costs related to the Company’s remote healthcare systems in the amount of $24,842 for the period September 20, 2016 through December 31, 2016.

 

In August 2016, the Company’s contract with its primary IVF drug rebate program was cancelled, resulting in a 95.4% reduction in IVF costs, and discontinuation of rebates.  The total IVF purchases for 2017 and 2016, respectively, were $784,052 and $16,957,962, or 24.5% and 74.5% of total revenues and 24.3% and 88.4% of cost of sales. The total discontinued rebates received from the primary IVF drug rebate program in 2017 and 2016, respectively, were $46,822 and $1,775,792, or 1.5% and 7.8% of total revenues and 1.5% and 9.2% of cost of sales.

 

The Company has not yet launched its major business activity, which is medical diagnostics and testing.


Table of Contents

- 31 -



General and Administrative Expenses

 

For the year ended

 

 

 

 

December 31, 2017

 

December 31, 2016

 

Variances

 

Legal, accounting, and management services

$

1,028,195

 

$

1,903,288

 

$

(875,093

)

Stock compensation/stock option amortization

 

2,473,510

 

 

176,370

 

 

2,297,140

 

Salaries, taxes and benefits

 

1,727,554

 

 

1,152,187

 

 

575,367

 

Depreciation and amortization

 

345,492

 

 

214,194

 

 

131,298

 

Rent expense-office

 

116,285

 

 

160,080

 

 

(43,795

)

Travel, meals and entertainment

 

68,458

 

 

226,655

 

 

(158,197

)

Publicity and promotion

 

22,368

 

 

277,967

 

 

(255,598

)

Office supplies and miscellaneous expenses

 

645,114

 

 

771,393

 

 

(126,280

)

Total general and administrative expenses

$

6,426,976

 

$

4,882,134

 

$

1,544,842

 

 

General and administrative expenses in the amount of $6,426,976 for the year ended December 31, 2017, were comprised of $1,028,195 in legal, accounting and management fees, $2,473,510 in stock compensation/stock option amortization, $1,727,554 in salaries and related taxes and benefits, $345,492 in depreciation and amortization, $116,285 in rent expense, $68,458 in travel, meals and entertainment, $22,368 in publicity and promotion, and $645,114 of office overhead and other general and administrative expenses.

 

General and administrative expenses in the amount of $4,882,134 for the year ended December 31, 2016, were comprised of $1,903,288 in legal, accounting and management fees, $176,370 in stock compensation/stock option amortization, $1,152,187 in salaries and related taxes and benefits, $214,194 in depreciation and amortization, $160,080 in rent expense, $226,655 in travel, meals and entertainment, $277,967 in publicity and promotion, and $771,393 of office overhead and other general and administrative expenses.

 

General and administrative expenses for the year ended December 31, 2017, were $6,424,376 as compared to $4,882,134 for the year ended December 31, 2016, which resulted in an increase in general and administrative expenses for the current year of $1,544,842.

 

Significant changes in general and administrative expenses of $1,544,842 during the year 2017 compared to 2016 were attributable to the following items:

 

a decrease in legal, accounting and consulting services of $875,093, primarily due to a decrease in legal costs of $786,689 resulting from a reduction in legal counsel time spent for pending litigation matters during 2017 compared to 2016; a decrease of $137,453 resulting from consultants retained for litigation and valuation purposes in the prior year, compared to no such expense in the current year; an increase in accounting and audit fees of $222,888 due to a change in auditors, resulting in 2016 and 2017 audit fees charged by the newly engaged audit firm in the current year; a decrease in consulting fees of $180,000 resulting from a change in management; and an increase in miscellaneous management fees of $6,161; and 

 

an increase in stock compensation/stock option amortization of $2,297,140, primarily due to stock awards granted in the current year resulting in stock compensation of $1,794,000 expensed in the current year, compared to $22,250 in the prior year; and the issuance of additional stock options in the current year, resulting in an increase in stock option amortization of $435,556; and the exercise of employee stock options, resulting in stock compensation expense of $67,584, compared to no such expense in the prior year; and  

 

an increase in salaries and fees, and related taxes and benefits of $575,367, primarily due to an increase in officer compensation of $278,128, staff compensation of $105,271, related payroll taxes of $47,324, and employee benefits of $51,126, resulting from only 5 months of expense in the prior year compared to 12 months of expense in the current year; and an increase in penalties on unpaid payroll and state income taxes of $74,584; and an increase in miscellaneous fees for outside services in the amount of $18,934; and 

 

an increase in depreciation and amortization of $131,298, primarily due to fully depreciated assets, resulting in a decrease in  depreciation of $12,806; and fully amortized intangible assets, resulting in a decrease in amortization of $145,834; and the acquisition of additional intangible assets, resulting in partial year amortization expense of $289,938 during the current year compared to $3,698 in the prior year; and 

 

a decrease in rent expense for office space of $43,795, due to vacating office space in July 2016, resulting in a reduction in rent expense of $43,795; and 

 

a decrease in travel, meals and entertainment of $158,197, primarily due to a reduction in travel costs of $91,591, and meals and entertainment of $66,606 resulting from the reduction in pharmacy segment revenues; and  

 

a decrease in publicity and promotion of $255,598 primarily due to the cessation of certain IVF sales resulting in the reduction in IVF video development; and 

 

a decrease in office supplies and miscellaneous expenses of $126,280, due to a decrease in automobile expense of $24,319, bank and wire fees of $14,557, computer and internet costs of $16,238, insurance expense of $11,632, office expense of $36,451, parking of $19,458, pension plan contributions of $13,543, licenses and permits of $13,260, state income and franchise taxes of $18,547,and other general office expenses of $4,195, and an increase in bad debt expense of $38,040, pension plan administrative costs of $2,554, and communication costs of $5,330, primarily resulting from the reduction in staff and general overhead due to decline in pharmacy operations. 

 

General and administrative expenses for both 2017 and 2016 were incurred for the purpose of advancing the Company closer to its financing and operating goals in the bio-medical sector, as well as the business operations of the Pharmacy segment, and the Remote Health Care segment beginning September 20, 2016, and the Behavioral Health Systems segment beginning March 22, 2017.

 

Net Loss

 

During the year ended December 31, 2017, the Company incurred a net loss of $13,876,506 compared with a net loss of $13,181,859 for the year ended December 31, 2016. The increase in net loss of $694,647 is attributable to a decrease in gross profits of $3,592,246, a decrease in sales, marketing and pharmacy expense of $1,165,500, an increase in general and administrative expenses of $1,544,842, a decrease in impairment losses of $4,016,924, an increase in discount amortization of $350,000, and an increase in interest expense, net of interest/dividend income, of $389,983.


- 32 -



Liquidity and Capital Resources

 

Working Capital

At December 31,

 

Increase

 

 

2017

 

2016

 

(Decrease)

 

Current assets

$

55,419

 

$

1,415,193

 

$

(1,359,774

)

Current liabilities

 

8,064,824

 

 

4,410,253

 

 

3,651,971

 

Working capital (deficit)

$

(8,009,405

)

$

(2,995,060

)

$

(5,011,745

)

 

As at December 31, 2017, the Company had cash in the amount of $2,604 compared to $63,363 as of December 31, 2016.

 

The Company had a working capital deficit of $8,009,405 as of December 31, 2017, compared to a working capital deficit of $2,995,060 at December 31, 2016. The increase in working capital deficit of $5,014,345 is primarily attributable to a decrease in cash of $60,759, accounts receivable of $721,654, rebates receivable of $72,030, inventory of $410,148, employee advances of $9,202, and prepaid expenses of $85,981, and an increase in accounts payable and accrued expenses of $2,053,129, pension plan contributions payable of $1,748, convertible notes payable of $741,000, and other related party payable of $858,694.

 

Cash Flows

For the year ended

 

Increase

 

 

December 31, 2017

 

December 31, 2016

 

(Decrease)

 

Net cash used in operating activities

$

(1,358,435

)

$

(424,926

)

$

(933,509

)

Net cash used in investing activities

 

––

 

 

(94,099

)

 

94,099

 

Net cash provided by (used in) financing activities

 

1,297,676

 

 

(330,011

)

 

1,627,687

 

Increase (decrease) in cash

$

(60,759

)

$

(849,036

)

$

788,277

 

 

Cash Flows from Operating Activities

 

During the year ended December 31, 2017, the Company used $1,358,435 of cash flow for operating activities, compared with $424,926 for the year ended December 31, 2016. The increase in cash used in operating activities of $933,509 is primarily attributable to an increase in the net loss from operations of $694,647, an increase in depreciation and amortization of $131,298, a decrease in impairment losses of $4,016,924, an increase in stock compensation/stock option amortization of $2,108,140, an increase in allowance for bad debt of $37,957, a decrease in the changes in accounts receivable of $281,674, inventories of $10,860, loans receivable of $93,990, and pension plan contribution payable of $9,074, and an increase in the changes in prepaid expenses of $68,510, other assets of $750, accounts payable and accrued expenses of $804,035, and related party payables of $672,970.

 

Cash Flows from Investing Activities

 

During the years ended December 31, 2017, the Company used no cash flow for investing activities, compared to $94,099 for the year ended December 31, 2016.  The decrease in cash used for investing activities is the result of the Company's purchase of professional equipment in the amount of $94,099 in the prior year compared to none in the current year.

 

Cash Flows from Financing Activities

 

During the year ended December 31, 2017, the Company was provided with $1,297,676 in cash flows from financing activities, compared to using $330,011 during the year ended December 31, 2016. The increase in cash flows provided by financing activities of $1,627,687 is attributable to a decrease in the repayment of notes payable of $540,187, and an increase in proceeds from convertible notes payable of $741,000, proceeds from related party convertible notes payable of $50,000, proceeds from the issuance of preferred shares of $100,000, and proceeds from the issuance of common stock of $196,500, of which $2,500 was in connection with the acquisition of certain intangible assets.

 

As at December 31, 2017, related parties are due a total of $2,451,028, consisting of $927,144 in accrued compensation owed to officers; $61,570 in cash advances from officers and beneficial owners to the Company for operating expenses; and $1,352,254 in related party notes payable, of which $1,167,254 contain conversion features.

 

The Company has issued convertible promissory notes to its principals in the aggregate sum of $1,167,254, representing cash loans and unpaid compensation.  The notes bear interest at a rate of between 5% and 12.5% per annum, mature between December 31, 2015 and May 8, 2018, and contain repayment provisions to convert the debt into common stock of the Company at an exercise price of between $0.10 to $0.20 per share. The conversion price of $0.10 resulted in a beneficial conversion feature.  As a result, the difference between the conversion rate and the market rate in the aggregate of $474,394 was classified as discounts on the notes, and was fully expensed in prior years. During the year ended December 31, 2017, interest in the amount of $76,511 was expensed, of which $16,833 was paid to the note holders in cash.  As of December 31, 2017, a total of $261,342 in interest has been accrued.

 

The Company, through its wholly-owned subsidiary, RoxSan, issued two promissory notes to J. Michael Redmond in the principal sum of $197,000, for cash loans made to RoxSan for overhead requirements during the year ended December 31, 2016.  The notes bear interest at a rate of 5% per annum and mature October 14, 2016 and November 29, 2016.  During the year ended December 31, 2017, interest in the amount of $9,250 was expensed.  As of December 31, 2017, a total of $11,823 in interest has been accrued and is included as part of accrued expenses on the accompanying consolidated balance sheets.

 

The Company’s principal sources of funds have been from the Company’s sales of its preferred and common stock, loans from related parties and third-party lenders, net revenues generated from the sale of prescription pharmaceuticals, and its remote healthcare sales and services.

 

Future Financings

 

The Company has suffered recurring losses from operations. The continuation of the Company’s operations is dependent upon the Company’s attaining and maintaining profitable operations and raising additional capital as needed. The Company anticipates that it will have to raise additional funds through private placements of the Company’s equity securities and/or debt financing to complete its business plan.

 

The Company will require additional financing in order to proceed with its plan of operations, including approximately $3,000,000 over the next 12 months to pay for its ongoing expenses. These cash requirements include working capital, general and administrative expenses, the development of the Company’s product line, and the pursuit of acquisitions. These cash requirements are in excess of the Company’s current cash and working capital resources. Accordingly, the Company will require additional financing in order to continue operations and to repay its liabilities. There is no assurance that the financing will be completed as planned or at all. If the Company is unable to secure adequate capital to continue the Company’s planned operations, the Company’s shareholders may lose some or all of their investment and the Company’s business may fail.

 

The Company anticipates continuing to rely on equity sales of its common stock in order to continue to fund its business operations. Issuances of additional shares will result in dilution to the Company’s existing stockholders. There is no assurance that the Company will achieve any additional sales of its equity securities or arrange for debt or other financing to fund its planned business activities.

 


Table of Contents

- 33 -



Personnel

 

As of December 31, 2017, the Company had 8 employees, excluding its directors and executive officers. Currently, the Company has 8 employees, excluding its directors and executive officers.

 

Contractual Obligations

 

As a “smaller reporting company”, the Company is not required to provide the information required by this Item.

 

Going Concern

 

The Company has incurred losses since inception resulting in an accumulated deficit of $33,773,141, and further losses are anticipated in the development of its business. The Company’s ability to continue as a going concern is dependent upon its ability to generate profitable operations in the future and/or to obtain the necessary financing to meet its obligations and repay its liabilities arising from normal business operations when they come due, which may not be available at commercially reasonable terms. There can be no assurance that the Company will be able to generate profitable operations and/or continue to raise funds, in which case the Company may be unable to meet its obligations and the Company may cease operations. These factors, among others, raise substantial doubt about the Company’s ability to continue as a going concern.

 

The audited consolidated financial statements included with this annual report have been prepared on the going concern basis which assumes that adequate sources of financing will be obtained as required and that the Company’s assets will be realized and liabilities settled in the ordinary course of business. Accordingly, the audited consolidated financial statements do not include any adjustments related to the recoverability of assets and classification of assets and liabilities that might be necessary should the Company be unable to continue as a going concern.

 

Off-Balance Sheet Arrangements

 

The Company has no significant off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on the Company’s financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that are material to stockholders.

 

Critical Accounting Policies

 

The discussion and analysis of the Company’s financial condition and results of operations are based upon the Company’s consolidated unaudited financial statements, which have been prepared in accordance with the accounting principles generally accepted in the United States of America. Preparing financial statements requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue, and expenses. These estimates and assumptions are affected by management’s application of accounting policies. The Company believes that understanding the basis and nature of the estimates and assumptions involved with the following aspects of the Company’s financial statements is critical to an understanding of its consolidated financial statements.

 

Included in the Acquisition Agreement for RoxSan Pharmacy, Inc., and as part of the negotiated purchase price, were representations and warranties made by the former owner involving certain primary revenue streams and related contracts.  Shortly after the closing, however, management discovered that these representations were substantially inaccurate and/or completely false. These inaccuracies, and the improper disclosures and/or omissions made by the former owner during negotiations, would have significantly affected the purchase price and related note payable issued under the Acquisition Agreement. Management engaged a third-party to perform a valuation of the Pharmacy, utilizing revised inputs that more accurately reflected the Pharmacy's revenue streams as of the date of Acquisition.  The valuation performed resulted in a fair market value of $4.7 to $5.2 million. After careful consideration, and based upon these significant differences, management has determined that the purchase price and related promissory note of $20,500,000 does not fairly represent the fair market value at the date of purchase.  The Company has, therefore, applied a discount to the note of $15.3 million, to reduce the purchase price and related note to its estimated fair market value of $5.2 million, utilizing the higher value on the range as a conservative measure.  The discount is being amortized over thirty-six (36) months.

 

ITEM 7A.QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK  

 

As a “smaller reporting company”, the Company is not required to provide the information required by this Item.

 

 

ITEM 8.FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA  

 

The Company’s audited consolidated financial statements are stated in United States dollars (US$) and are prepared in accordance with United States Generally Accepted Accounting Principles.

 

The following audited consolidated financial statements are filed as part of this annual report:

 

Report of Independent Registered Public Accounting Firm

F-1

 

 

Consolidated Balance Sheets as at December 31, 2017 and 2016

F-2

 

 

Consolidated Statements of Operations for the years ended December 31, 2017 and 2016

F-3

 

 

Consolidated Statements of Changes in Stockholders' Deficit for the years ended December 31, 2017 and 2016

F-4

 

 

Consolidated Statements of Cash Flows for the years ended December 31, 2017 and 2016

F-5

 

 

Notes to the Consolidated Financial Statements for the years ended December 31, 2017 and 2016

F-6


- 34 -



 

FREEDMAN & GOLDBERG

 

CERTIFIED PUBLIC ACCOUNTANTS

 

 

A PROFESSIONAL CORPORATION

 

 

 

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

 

 

We have audited the accompanying consolidated balance sheets of Parallax Health Sciences, Inc., and subsidiaries (the “Company”) as of December 31, 2017 and 2016, and the related statements of operations, stockholders’ deficit, and cash flows for each of the years in the two-year period ended December 31, 2017. Parallax Health Sciences, Inc.’s management is responsible for these financial statements. Our responsibility is to express an opinion on these financial statements based on our audits.

 

We conducted our audits in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. The company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. Our audits included consideration of internal control over financial reporting as a basis for designing audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the company’s internal control over financial reporting. Accordingly, we express no such opinion. An audit also includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements, assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion.

 

In our opinion, the financial statements referred to above present fairly, in all material respects, the financial position of Parallax Health Sciences, Inc. as of December 31, 2017 and 2016, and the results of its operations and its cash flows for each of the years in the two-year period ended December 31, 2017, in conformity with accounting principles generally accepted in the United States of America.

 

The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 1 to the financial statements, the Company has suffered recurring losses from operations and has a net capital deficiency that raise substantial doubt about its ability to continue as a going concern. Management's plans in regard to these matters are also described in Note 1. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

 

 

 

Freedman & Goldberg

 

/s/ Freedman & Goldberg

 

Farmington Hills, Michigan

September 7, 2018

 

 

31150 Northwestern Highway, Suite 200, Farmington Hills, Michigan 48334  (248) 626-2400  Fax (248) 626-4298

2444 East Hill Road, Grand Blanc, Michigan 48439  (810) 694-0336  Fax (810) 694-9789

Website: freedmangoldberg.com


Table of Contents

- F-1 -



PARALLAX HEALTH SCIENCES, INC.

CONSOLIDATED BALANCE SHEETS

 

 

December 31, 2017

 

December 31, 2016

 

ASSETS

 

 

 

 

 

 

Current assets

 

 

 

 

 

 

Cash and cash equivalents

$

2,604

 

 

63,363

 

Accounts receivable, net

 

44,131

 

 

765,785

 

Rebates receivable

 

––

 

 

72,030

 

Inventories

 

––

 

 

410,148

 

Employee advances

 

1,800

 

 

11,002

 

Prepaid expenses

 

6,884

 

 

92,865

 

Total current assets

 

55,419

 

 

1,415,193

 

 

 

 

 

 

 

 

Loans receivable - long-term

 

169,902

 

 

169,902

 

Property and equipment, net

 

10,000

 

 

39,359

 

Intangible assets, net

 

2,298,094

 

 

191,727

 

Goodwill

 

785,060

 

 

785,060

 

Deposits

 

22,000

 

 

22,750

 

 

 

 

 

 

 

 

TOTAL ASSETS

$

3,340,475

 

 

2,623,991

 

 

 

 

 

 

 

 

LIABILITIES AND STOCKHOLDERS' DEFICIT

 

 

 

 

 

 

Current liabilities

 

 

 

 

 

 

Accounts payable and accrued expenses

$

6,027,480

 

 

3,974,351

 

Pension plan contribution payable

 

12,570

 

 

10,822

 

Notes payable, convertible

 

741,000

 

 

––

 

Note payable, related party

 

185,000

 

 

185,000

 

Related party payables

 

1,098,774

 

 

240,080

 

Total current liabilities

 

8,064,824

 

 

4,410,253

 

 

 

 

 

 

 

 

Long-term liabilities

 

 

 

 

 

 

License fee payable, net of unamortized discount

 

1,890,000

 

 

540,000

 

Royalties payable

 

1,000,000

 

 

200,000

 

Notes and loans payable, unsecured

 

95,975

 

 

95,975

 

Note payable, convertible

 

144,000

 

 

144,000

 

Notes payable, related party, convertible

 

1,167,254

 

 

1,357,254

 

Notes payable, secured, net of unamortized discount

 

18,368,066

 

 

13,450,390

 

Total long-term liabilities

 

22,665,295

 

 

15,787,619

 

Total liabilities

 

30,730,119

 

 

20,197,872

 

 

 

 

 

 

 

 

Stockholders' deficit

 

 

 

 

 

 

Preferred stock, $.001 par, 10,000,000 shares authorized,

 

864

 

 

834

 

863,691 and 833,691 issued and outstanding

 

 

 

 

 

 

as of December 31, 2017 and 2016, respectively

 

 

 

 

 

 

Common stock, $.001 par, 250,000,000 shares authorized,

 

136,754

 

 

107,067

 

136,754,530 and 107,066,774 issued and outstanding

 

 

 

 

 

 

as of December 31, 2017 and 2016, respectively

 

 

 

 

 

 

Additional paid in capital - preferred

 

665,803

 

 

515,833

 

Additional paid in capital - common

 

5,580,668

 

 

1,700,612

 

Subscriptions receivable

 

(592)

 

 

(1,592

)

Accumulated deficit

 

(33,773,141

)

 

(19,896,635

)

Total stockholders' deficit

 

(27,389,644

)

 

(17,573,881

)

 

 

 

 

 

 

 

TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT

$

3,340,475

 

$

2,623,991

 

 

 

The accompanying notes are an integral part of these financial statements


Table of Contents

- F-2 -



PARALLAX HEALTH SCIENCES, INC.

CONSOLIDATED STATEMENTS OF OPERATIONS

 

 

For the year ended

 

 

December 31, 2017

 

December 31, 2016

 

 

 

 

 

 

 

 

Revenue

$

3,195,144

 

$

22,749,087

 

Cost of sales

 

3,226,247

 

 

19,187,944

 

Gross profit

 

(31,103

)

 

3,561,143

 

 

 

 

 

 

 

 

Sales, marketing, and pharmacy expenses

 

660,400

 

 

1,825,900

 

General and administrative expenses

 

6,426,976

 

 

4,882,134

 

 

 

 

 

 

 

 

Operating loss

 

(7,118,479

)

 

(3,146,891

)

 

 

 

 

 

 

 

Other income (expenses)

 

 

 

 

 

 

Impairment loss

 

––

 

 

(4,016,924

)

Discount amortization

 

(5,450,000

)

 

(5,100,000

)

Interest expense, net of interest/dividend income

 

(1,308,027

)

 

(918,044

)

Total other income (expenses)

 

(6,758,027

)

 

(10,034,968

)

 

 

 

 

 

 

 

Net loss

$

(13,876,506

)

$

(13,181,859

)

 

 

 

 

 

 

 

Net (loss) per common share - basic

$

(0.115

)

$

(0.116

)

Net (loss) per common share - diluted

$

(0.081

)

$

(0.083

)

 

 

 

 

 

 

 

Weighted average common shares outstanding - basic

 

120,493,618

 

 

113,689,042

 

Weighted average common shares outstanding - diluted

 

172,353,832

 

 

158,497,392

 

 

 

The accompanying notes are an integral part of these financial statements

 


Table of Contents

- F-3 -



 

PARALLAX HEALTH SCIENCES, INC.

STATEMENT OF STOCKHOLDERS DEFICIT

FROM JANUARY 1, 2016 TO DECEMBER 31, 2017

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

PREFERRED STOCK

 

COMMON STOCK

 

ADDITIONAL PAID IN CAPITAL

 

DEFERRED

 

SUBSCRIPTIONS

 

ACCUMULATED

 

 

 

 

SHARES

 

AMOUNT

 

SHARES

 

AMOUNT

 

PREFERRED

 

COMMON

 

COMPENSATION

 

RECEIVABLE

 

DEFICIT

 

TOTAL

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Balance, January 1, 2016

823,691

 

$

824

 

120,566,774

 

$

120,567

 

$

465,843

 

$

1,352,228

 

$

(321,886

)

$

(192

)

$

(6,714,776

)

$

(5,097,392

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Issuance of preferred stock for cash

10,000

 

 

10

 

 

 

 

 

 

 

49,990

 

 

 

 

 

 

 

 

 

 

 

 

 

 

50,000

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Cancellation of common stock

 

 

 

 

 

(20,000,000

)

 

(20,000

)

 

 

 

 

20,000

 

 

 

 

 

 

 

 

 

 

 

––

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Issuance of common stock for acquisition of subsidiary

 

 

 

 

 

5,000,000

 

 

5,000

 

 

 

 

 

285,000

 

 

 

 

 

(5,000

)

 

 

 

 

285,000

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Issuance of common stock for services

 

 

 

 

 

1,500,000

 

 

1,500

 

 

 

 

 

211,250

 

 

 

 

 

(1,500

)

 

 

 

 

211,250

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Grant of stock options to consultants

 

 

 

 

 

 

 

 

 

 

 

 

 

 

57,460

 

 

(57,460

)

 

 

 

 

 

 

 

––

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Grant of stock options to employees

 

 

 

 

 

 

 

 

 

 

 

 

 

 

7,580

 

 

(7,580

)

 

 

 

 

 

 

 

––

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Amortization of stock options

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

154,020

 

 

 

 

 

 

 

 

154,020

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Subscriptions received

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

5,100

 

 

 

 

 

5,100

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net loss

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(13,181,859

)

 

(13,181,859

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Balance, December 31, 2016

833,691

 

$

834

 

107,066,774

 

$

107,067

 

$

515,833

 

$

1,933,518

 

$

(232,906

)

$

(1,592

)

$

(19,896,635

)

$

(17,573,881

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Issuance of preferred stock for cash

30,000

 

 

30

 

 

 

 

 

 

 

149,970

 

 

 

 

 

 

 

 

 

 

 

 

 

 

150,000

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Issuance of common stock for acquisition of intangible assets

 

 

 

 

 

2,500,000

 

 

2,500

 

 

 

 

 

622,500

 

 

 

 

 

 

 

 

 

 

 

625,000

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Issuance of common stock for cash

 

 

 

 

 

3,950,000

 

 

3,950

 

 

 

 

 

193,550

 

 

 

 

 

 

 

 

 

 

 

197,500

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Issuance of common stock for services

 

 

 

 

 

3,000,000

 

 

3,000

 

 

 

 

 

747,000

 

 

 

 

 

(3,000)

 

 

 

 

 

747,000

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Issuance of common stock for debt settlement

 

 

 

 

 

2,100,000

 

 

2,100

 

 

 

 

 

112,900

 

 

 

 

 

 

 

 

 

 

 

115,000

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Conversion of related party debt

 

 

 

 

 

3,906,154

 

 

3,906

 

 

 

 

 

521,827

 

 

 

 

 

 

 

 

 

 

 

525,733

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Grant of stock options to consultants

 

 

 

 

 

 

 

 

 

 

 

 

 

 

1,430,800

 

 

(1,430,800

)

 

 

 

 

 

 

 

––

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Grant of stock options to employees

 

 

 

 

 

 

 

 

 

 

 

 

 

 

495,950

 

 

(495,950

)

 

 

 

 

 

 

 

––

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Grant of stock awards for services

 

 

 

 

 

13,950,000

 

 

13,950

 

 

 

 

 

2,835,300

 

 

(2,838,500

)

 

(10,250

)

 

 

 

 

500

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Exercise of stock options-employees

 

 

 

 

 

281,602

 

 

281

 

 

 

 

 

67,303

 

 

 

 

 

 

 

 

 

 

 

67,584

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Forfeiture of stock options

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(246,985

)

 

246,985

 

 

 

 

 

 

 

 

––

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Change in value of stock options

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(3,983

)

 

3,983

 

 

 

 

 

 

 

 

––

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Amortization of stock options

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

589,678

 

 

 

 

 

 

 

 

589,678

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Amortization of stock awards

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

1,028,498

 

 

 

 

 

 

 

 

1,028,498

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Subscriptions received

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

14,250

 

 

 

 

 

14,250

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net loss

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(13,876,506

)

 

(13,876,506

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Balance, December 31, 2017

863,691

 

$

864

 

136,754,530

 

$

136,754

 

$

665,803

 

$

8,709,680

 

$

(3,129,012

)

$

(592

)

$

(33,773,141

)

$

(27,389,644

)

 

The accompanying notes are an integral part of these financial statements


Table of Contents

- F-4 -



PARALLAX HEALTH SCIENCES, INC.

 

CONSOLIDATED STATEMENTS OF CASH FLOWS

 

 

 

 

 

For the year ended

 

 

December 31, 2017

 

December 31, 2016

 

Cash flows from operating activities:

 

 

 

 

 

 

Net loss

$

(13,876,506

)

$

(13,181,859

)

Adjustments to reconcile net loss to net cash used in operating activities:

 

 

 

 

 

 

Depreciation and amortization

 

345,492

 

 

214,194

 

Impairment loss

 

––

 

 

4,016,924

 

Stock compensation/stock option expense

 

2,473,510

 

 

365,370

 

Discount amortization

 

5,450,000

 

 

5,100,000

 

Allowance for bad debt

 

114,957

 

 

77,000

 

Changes in operating assets and liabilities:

 

 

 

 

 

 

Decrease in trade and other receivables

 

687,929

 

 

969,603

 

Decrease in inventories

 

410,148

 

 

421,008

 

Decrease in prepaid expenses

 

85,981

 

 

17,471

 

Decrease in loans receivable

 

––

 

 

93,990

 

Decrease in other assets

 

750

 

 

––

 

Increase in accounts payable and accrued expenses

 

1,983,116

 

 

1,179,081

 

Increase in pension plan contribution payable

 

1,748

 

 

10,822

 

Increase in related party payables

 

964,440

 

 

291,470

 

Net cash used in operating activities

 

(1,358,435

)

 

(424,926

)

 

 

 

 

 

 

 

Cash flows from investing activities:

 

 

 

 

 

 

Purchase of professional equipment

 

––

 

 

(94,099

)

Net cash used in investing activities

 

––

 

 

(94,099

)

 

 

 

 

 

 

 

Cash flows from financing activities:

 

 

 

 

 

 

Proceeds from notes payable

 

100,000

 

 

100,000

 

Repayment of notes payable

 

(194,824

)

 

(735,011

)

Proceeds from convertible notes payable

 

741,000

 

 

––

 

Proceeds from convertible note payable, related party

 

300,000

 

 

250,000

 

Proceeds from issuance of preferred shares

 

150,000

 

 

50,000

 

Proceeds from issuance of common shares

 

199,000

 

 

––

 

Proceeds from issuance of common shares for acquisition

 

2,500

 

 

5,000

 

Net cash provided by (used in) financing activities

 

1,297,676

 

 

(330,011

)

 

 

 

 

 

 

 

Net decrease in cash

 

(60,759

)

 

(849,036

)

Cash - beginning of period

 

63,363